Supplementary Appendix
Supplement Table S1. Search Strategy on Medline, Embase and CENTRAL
Supplement Table S2. Main Characteristics of Included Trials
Supplement Table S3. Patient Characteristics of Included Trials
Supplement Table S4. Sensitivity Analysis of Definite or Probable Stent Thrombosis Within 1 Year
Supplement Figure S1. Risk of Bias Assessment Summary
Supplement Figure S2. Ranks for Study Stents Regarding Definite or Probable Stent Thrombosis
Supplement Figure S3. Definite or Probable Stent Thrombosis at the Longest Follow-Up Available
Supplement Figure S4. Definite or Probable Stent Thrombosis, Early (≤30 days)
Supplement Figure S5. Definite or Probable Stent Thrombosis, Late (31-365 days)
Supplement Figure S6. Definite or Probable Stent Thrombosis, Very Late (>365 days)
Supplement Figure S7. Definite or Probable Stent Thrombosis, Late and Very Late (>30 days)
Supplement Figure S8. Definite Stent Thrombosis with Reference to Bare Metal Stent
Supplement Figure S9. Inconsistency Plot for Triangular Loops
Supplement Figure S10. Target Vessel Revascularization Within 1 Year
Supplement Figure S11. All-Cause Death Within 1 Year
Supplement Figure S12. Cardiac Death Within 1 Year
Supplement Figure S13. Network Plot of Sensitivity Analysis for Trials with Low Risk of Bias
Supplement Figure S14. Sensitivity Analysis for Trials with Low Risk of Bias
Supplementary Table S1. Search Strategy on Medline, Embase and Central
Medline
#1
#2
#3
#4
#5
#6
#7
#8
#9
#10
#11
#12
#13
#14
#15
#16
#17
#18
#19
(randomized controlled trial[Publication Type] OR (randomized[Title/Abstract] AND
controlled[Title/Abstract] AND trial[Title/Abstract]))
"stents"[MeSH Terms] OR "stents"[tiab] OR "stent"[tiab]
(#1) AND (#2)
"bare metal"[All Fields]
"drug-eluting stents"[All Fields] OR "drug-eluting stent"[All Fields] OR "drug-coated stents"[All
Fields] OR "drug-coated stent"[All Fields] OR "drug eluting"[All Fields]
(("sirolimus-eluting" OR "rapamycin-eluting" OR "paclitaxel-eluting" OR "zotarolimus-eluting"
OR "everolimus-eluting") AND ("stents" OR "stent")) OR ("cypher" OR "taxus" OR "endeavor"
OR "resolute" OR "xience" OR "xience-V" OR "promus" OR "promus-element")
(#5) OR (#6)
("bioabsorbable"[tiab] OR "biodegradable"[tiab]) AND ("polymers"[MeSH Terms] OR
"polymers"[All Fields] OR "polymer"[All Fields])
"drug-eluting stent"[All Fields] OR "drug-eluting stent"[All Fields] OR "drug-coated stents"[All
Fields] OR "drug-coated stent"[All Fields] OR "drug eluting"[All Fields]
(#8) AND (#9)
(("biolimus-eluting" OR "everolimus-eluting") AND ("stents" OR "stent")) OR ("biomatrix" OR
"nobori" OR "synergy")
(#10) OR (#11)
("Peripheral Arterial Disease"[Mesh] OR "Peripheral Vascular Diseases"[Mesh]) OR
("Peripheral Arterial Disease"[TIAB] OR "Peripheral Vascular Diseases"[TIAB])
registries[MeSH Terms] OR "registries"[All Fields] OR "registry"[All Fields]
observational[All Fields] AND ("clinical trials as topic"[MeSH Terms] OR ("clinical"[All Fields]
AND "trials"[All Fields] AND "topic"[All Fields]) OR "clinical trials as topic"[All Fields] OR
"study"[All Fields] OR "biomedical research"[MeSH Terms] OR ("biomedical"[All Fields] AND
"research"[All Fields]) OR "biomedical research"[All Fields])
((#13) OR (#14)) OR (#15)
((#4) OR (#7)) OR #12
(#3) AND (#17)
(18) NOT (#16)
Embase
#1
#2
#3
#4
#5
#6
#7
#8
#9
#10
#11
#12
#13
‘randomized controlled trial’/exp AND [embase]/lim
‘stent’/exp AND [embase]/lim
#1 AND #2
‘bare metal stent’/exp AND [embase]/lim
‘drug eluting stent’/exp AND [embase]/lim
bioabsorbable AND ‘polymer’/exp AND ‘drug’/exp AND eluting and ‘stent’/exp AND
[embase]/lim
biodegradable AND ‘polymer’/exp AND ‘drug’/exp AND eluting and ‘stent’/exp AND
[embase]/lim
#4 OR #5 OR #6 OR #7
‘peripheral occlusive artery disease’/exp AND [embase]/lim
‘register’/exp AND [embase]/lim
‘observational study’/exp AND [embase]/lim
#9 OR #10 OR #11
#3 AND #8 NOT #12
CENTRAL
#1
MeSH descriptor: Stents] explode all trees
#2
bare metal stent
#3
#4
#5
drug-eluting stent
sirolimus-eluting or rapamycin-eluting or paclitaxel-eluting or zotarolimus-eluting or
everolimus-eluting or cypher or taxus or endeavor or resolute or xience or xience-V or
promus or promus-element
bioabsrobable or biodegradable or polymer
#6
biolimus-eluting or everolimus-eluting or biomatrix or nobori or synergy
#7
#2 or #3 or #4 or #5 or #6
#8
MeSH descriptor: [Peripheral Arterial Disease] explode all trees
#9
MeSH descriptor: [Registries] explode all trees
#10
MeSH descriptor: [Comparative Study] explode all trees
#11
#8 or #9 or #10
#12
(#1 and #7) not #11
Supplementary Table S2. Main Characteristics of Included Trials
Trials
Stent Comparison
(Patient Number)
Primary Endpoint
Design
Major Inclusion Criteria
Main Results
Follow-Up
SES vs. BMS
(120:118)
In-stent LL at 6 months
Multicenter, superiority
Stable or unstable angina
SES superior to BMS
5 years
PES vs. BMS
(118:59)
% stenosis at 4-6 months
Three-center, superiority
Stable or unstable angina
PES superior to BMS
6 months
E-SIRIUS
SES vs. BMS
(175:177)
MLD at 8 months
Multicenter, superiority
Stable or unstable angina
SES superior to BMS
9 months
SIRIUS
SES vs. BMS
(533:525)
TVF at 9 months
Multicenter, superiority
Stable or unstable angina
SES superior to BMS
5 years
TAXUS I
PES vs. BMS
(31:30)
MACE (death Q-wave MI, TVR,
ST) at 30 days
Three-center, feasibility
Stable or unstable angina
Promising results of PES
2 years
TAXUS II
BMS vs. PES
(270:266)
%NIH by IVUS at 6 months
Multicenter, superiority
Stable or unstable angina
PES superior to BMS
5 years
SES vs. BMS
(50:50)
MLD at 8 months
Multicenter, superiority
Stable or unstable angina
SES superior to BMS
9 months
SES-SMART
SES vs. BMS
(129:128)
In-segment binary restenosis at 8
months
Multicenter, superiority
Stable angina, ACS
SES superior to BMS
2 years
TAXUS IV
BMS vs. PES
(652:662)
TVR at 9 months
Multicenter, superiority
Stable or unstable angina
PES superior to BMS
5 years
SES vs. PES
(264:281)
Cost-effectiveness after 6 months
Single-center, superiority
All-comer design
DES (SES and PES) not
superior to BMS
18 months
Published in 2002
RAVEL
Published in 2003
ASPECT
Published in 2004
C-SIRIUS
Published in 2005
BASKET
DIABETES
SES vs. BMS
(80:80)
in-segment LL at 9 months
Multicenter, superiority
Diabetes
SES superior to BMS
5 years
ISAR-DESIRE
SES vs. PES
(100:100)
Binary restenosis at 6 months
Multicenter, superiority
ISR
DES superior to balloon
angioplasty;
SES superior to PES
1 year
ISAR-DIABETES
PES vs. SES
(125:125)
In-segment LL at 9 months
Multicenter, non-inferiority
(PES over SES)
Diabetes
SES superior to PES
9 months
Pache et al.
SES vs. BMS
(250:250)
Binary restenosis at 6 months
Multicenter, superiority
Stable or unstable angina
SES superior to BMS
1 year
SIRTAX
SES vs. PES
(503:509)
MACE (cardiac death, MI, TLR) at
9 months
Multicenter, superiority
Stable angina or ACS
SES superior to PES
5 years
CoCr-EES vs. BMS
(28:32)
in-stent LL at 6 months
Multicenter, superiority
Stable or unstable angina
CoCr-EES superior to BMS
5 years
BP-BES vs. BMS
(80:40)
In-stent LL at 6 months
Multicenter, superiority
Stable or unstable angina
BP-BES superior to BMS
6 months
STRATEGY
BMS vs. SES
(88:87)
Composite of death, MI, stroke,
binary restenosis at 8 months
Single-center, superiority
STEMI
(SES + tirofiban) superior to
(BMS + abciximab)
5 years
TAXi
PES vs. SES
(100:102)
MACE (Death, MI, TLR, ST)
Singer-center, superiority
All-comer design
SES similar to PES
3 years
TAXUS V
PES vs. BMS
(586:586)
TVR at 9 months
Multicenter, superiority
Stable or unstable angina
PES superior to BMS
9 months
TAXUS VI
PES vs. BMS
(219:227)
TVR at 9 months
Multicenter, superiority
Stable or unstable angina
PES superior to BMS
5 years
SES vs. PES
(37:33)
%NIH by 3D IVUS at 6 months
Single-center, superiority
Complex lesions or complex
patients
SES superior to PES
6 months
ZES-E vs. BMS
(598:599)
TVF at 9 months
Multicenter, superiority
Stable or unstable angina
ZES-E superior to BMS
5 years
SPIRIT FIRST
STEALTH
Published in 2006
Cervinka et al.
ENDEAVOR II
ENDEAVOR III
ZES-E vs. SES
(323:113)
In-segment LL at 8 months
Multicenter, non-inferiority
Stable or unstable angina
ZES-E inferior to SES
5 years
HAAMU-STENT
(abstract only)
BMS vs. PES
(82:82)
Not specified
Single-center, superiority
STEMI
PES (angiographically)
superior to BMS;
(clinically) similar with BMS
1 year
ISAR-SMART 3
PES vs. SES
(180:180)
In-stent LL between 6 and 8
months
Two-center, non-inferiority
Stable or unstable angina
PES inferior to SES
1 year
LONG-DES-II
SES vs. PES
(250:250)
In-segment binary restenosis at 6
months
Multicenter, superiority
Long lesion (≥25 mm)
SES superior to PES
9 months
Pasceri et al.
SES vs. BMS
(32:33)
ST at 6 months
Single-center, superiority
STEMI
SES similar to BMS
6 months
PASSION
PES vs. BMS
(310:309)
MACE (cardiac death, MI, TLR) at
12 months
Two-center, superiority
STEMI
PES not superior to BMS
5 years
PRISON II
BMS vs. SES
(100:100)
In-segment binary restenosis at 6
months
Two-center, superiority
Chronic total occlusion
SES superior to BMS
5 years
REALITY
SES vs. PES
(684:669)
In-lesion binary restenosis at 8
months
Multicenter, superiority
Stable or unstable angina
SES similar to PES
1 year
RRISC
BMS vs. SES
(37:38)
In-stent LL 6 months
Single-center, superiority
Saphenous vein grafts
SES superior to BMS
3 years
SCANDSTENT
SES vs. BMS
(163:159)
MLD at 6 months
Multicenter, superiority
Stable or unstable angina, recent
NSTEMI
SES superior to BMS
3 years
TYPHOON
SES vs. BMS
(355:357)
TVF at 1 year
Multicenter, superiority
STEMI
SES superior to BMS
4 years
BMS vs. SES
(60:60)
Composite of death, MI, and
recurrent ischemia at 1 year
Single-center, superiority
STEMI
SES superior to BMS
1 year
SES vs. BMS
(54:29)
In-stent LL at 6 months
Multicenter, superiority
Diabetes
SES superior to BMS
1 year
Published in 2007
de la Llera et al.
DECODE
Erglis et al
BMS vs. PES
(50:53)
clinical, angiographic, and IVUS
results at 6 months
Single-center, superiority
Unprotected LMCA
PES superior to BMS
3 years
BP-BES vs. PES
(85:35)
In-stent LL at 9 months
Multicenter, non-inferiority
Stable or unstable angina
BP-BES non-inferior to PES
2 years
Ortolani et al.
BMS vs. SES
(52:52)
In-segment LL at 9-month
Single-center, superiority
Stable or unstable angina,
NSTEMI, STEMI (> 48 hours)
SES superior to BMS
1 year
Pan et al (2007)
SES vs. PES
(103:102)
Binary restenosis & TLR at 1 year
single-center, superiority
Bifurcation lesions
SES superior to PES
1 year
Petronio et al.
SES vs. PES
(51:50)
NIHA% at 9 months
Single-center, superiority
Complex lesions
SES superior to PES
9 months
SCORPIUS
SES vs. BMS
(98:102)
In-segment LL at 8 months
Multicenter, superiority
Diabetes
SES superior to BMS
5 years
SELECTION
PES vs. BMS
(40:40)
%NIH by IVUS at 7 months
Single-center, superiority
STEMI
SESAMI
SES vs. BMS
(160:160)
Binary restenosis at 1 year
Single-center, superiority
STEMI
SES superior to BMS
5 years
Strozzi et al.
SES vs. BMS
(39:40)
Angiographic restenosis at 6
months
Single-center, superiority
(stent graft vs. SES vs.
BMS)
ACS
SES superior to BMS
6 months
SES vs. PES
(200:200)
In-segment binary restenosis at 6
months
Multicenter, superiority
Diabetes
SES superior to PES
4 years
DESSERT
BMS vs. SES
(75:75)
in-stent LL at 8 months
Multi-center, superiority
Diabetes
SES superior to BMS
1 year
Hong et al.
SES vs. PES
(85:84)
In-segment LL at 6 months
Multicenter, superiority
Diabetes
SES not superior to PES
3 years
LEADERS
BP-BES vs. SES
(857:850)
Composite of cardiac death, MI,
TVR at 9 months
Multicenter, non-inferiority
Stable angina, ACS
BP-BES noninfeior to SES
5 years
NOBORI 1 - Phase 1
Published in 2008
DES-DIABETES
PES
superior to BMS
7 months
Li et al. (2008)
SES vs. BMS
(24:24)
Plasma CRP & IL-6
MISSION!
SES vs. BMS
(158:152)
In-segment LL at 9 months
MULTISTRATEGY
BMS vs. SES
(372:372)
PROSIT
SORT OUT II
Single-vessel disease
SES superior to BMS
8 months
Single-center, superiority
STEMI
SES superior to BMS
5 years
MACE (death, MI TVR) at 8
months
Multicenter, superiority
STEMI
SES superior to BMS
3 years
SES vs. PES
(154:154)
MACE (death, MI, ST, TLR) at 12
months
Three-center, superiority
STEMI
Superiority no shown
3 years
SES vs. PES
(1065:1033)
MACE (cardiac death, MI, TLR,
TVR) at 5 years
Multicenter, superiority
All-comer design
Superiority not proven
5 years
CoCr-EES vs. PES
(669:333)
In-segment LL at 8 months
Multicenter, non-inferiority
Stable or unstable angina
CoCr-EES superior to PES
3 years
PES vs. BMS
(2257:749)
1) TLR, 2) composite of death, MI,
stroke, ST at 12 months
Multicenter, superiority
STEMI
PES superior to BMS
3 years
PES vs. SES
(302:305)
Composite of death, MI, TLR at 1
year
Multicenter, non-inferiority
Unprotected LMCA
PES non-inferior to SES
2 years
ISAR-TEST-2
SES vs. ZES-E
(335:339)
Binary restenosis at 6–8 months
Two-center, superiority
de novo stenosis
Dual-DES & SES superior to
ZES-E
2 years
ISAR-TEST-4
CoCr-EES vs. SES
(652:652)
Composite of cardiac death, MI,
TLR
Multicenter, non-inferiority
Stable angina, ACS
BP-DES non-inferior to PPDES (SES, CoCr EES)
3 years
Juwana et al.
SES vs. PES
(196:201)
In-stent LL at 9 months
Single-center, superiority
STEMI
SES superior to PES
1 year
Li et al. (2009)
SES vs. PES
(16:16)
Plasma CRP & IL-6
Single-center, superiority
Stable angina
with single-vessel disease
SES superior to PES
8 months
BP-BES vs. PES
(153:90)
In-stent LL at 9 months
Multicenter, non-inferiority
Stable or unstable angina
BP-BES non-inferior to PES
9 months
SPIRIT III
Published in 2009
HORIZONS-AMI
ISAR-LEFT-MAIN
NOBORI 1 - Phase 2
Single-center,
superiority
PASEO
BMS vs. PES vs. SES
(90:90:90)
TLR at 1 year
Single-center, superiority
STEMI
SES and PES superior to BMS
5 years
BMS vs. PES
(39:41)
In-segment binary restenosis at 12
months
Multicenter, superiority
Saphenous Vein Graft Lesions
PES superior to BMS
5 years
SPIRIT II
CoCr-EES vs. PES
(223:77)
In-stent LL at 6 months
Multi-center, non-inferiority
Stable or unstable angina
CoCr-EES non-inferior and
superior to PES
4 years
ZEST-AMI
ZES-E vs. SES vs. PES
(108:110:110)
MACE (death, MI, TVR) at 12
months
Multicenter, superiority
(SES over ZES-E,
PES over ZES-E)
STEMI
Superiority not shown
1 year
Multicenter, superiority
Large coronary artery
(stents ≥3.0 mm)
No difference among SES,
CoCr-EES, BMS
2 years
SOS
Published in 2010
BASKET-PROVE
COMPARE
SES vs. CoCr-EES vs. BMS composite of cardiac death, MI at 2
(775:774:765)
years
CoCr-EES vs. PES
(897:903)
Composite of death, MI, TVR at 12
months
Single-center, superiority
All-comer design
CoCr-EES superior to PES
2 years
ENDEAVOR IV
ZES-E vs. PES
(773:775)
TVF at 9 months
Multicenter, non-inferiority
Stable or unstable angina
ZES-E non-inferior to PES
3 years
GISSOC II-GISE
BMS vs. SES
(78:74)
in-segment MLD at 8 months
Multicenter, superiority
Chronic total occlusion
SES superior to BMS
2 years
GRACIA-3
BMS vs. PES
(216:217)
Binary restenosis at 12 months
Multicenter, superiority
STEMI
PES similar to BMS
1 year
ISAR-DESIRE 2
SES vs. PES
(225:225)
In-stent LL at 6-8 months
Multicenter, superiority
(PES over SES)
ISR of SES
PES not superior to SES
1 year
ZES-E vs. BMS
(33:11)
% of uncovered stent struts by
OCT at 6 months
Single-center, superiority
STEMI
ZES-E similar with BMS
1 year
ZES-R vs. CoCr-EES
(1140:1152)
TLF at 12 months
Multicenter, non-inferiority
All-comer design
ZES-R non-inferior to CoCrEES
2 years
ZES-E vs. SES
(1162:1170)
MACE (cardiac death, MI, CDTVR) at 9 months
Multicenter, superiority
All-comer design
SES superior to ZES-E
3 years
OCTAMI
RESOLUTE All Comers
SORT OUT III
SPIRIT IV
CoCr-EES vs. PES
(2458:1229)
TLF at 1 year
Multicenter, non-inferiority
and superiority
Stable or unstable angina
CoCr-EES non-inferior &
superior to PES
2 years
ZES-E vs. SES vs. PES
(883:878:884)
MACE (death, MI, TVR) at 12
months
Multicenter, non-inferiority
(ZES-E vs. SES) and
superiority (ZES-E vs.
PES)
Stable angina or ACS
ZES-E non-inferior to SES;
ZES-E superior to PES
2 years
CoCr-EES vs. SES
(149:151)
In-segment LL at 8 months
Multicenter, non-inferiority
Diabetes
CoCr-EES non-inferior to SES
1 year
EXCELLENT
CoCr-EES vs. SES
(1079:364)
In-segment LL at 9 months
Multicenter, non-inferiority
Stable or unstable angina,
recent MI
CoCr-EES were non-inferior to
SES
1 year
GARA-GARA
SES vs. PES
(400:400)
MACE (cardiac death, MI, CABG
or TLR) at 1 year
Single-center, superiority
All-comer design
SES superior to PES
1 year
ZES-E vs. SES vs. PES
(205:204:202)
MACE (cardiac death, MI, TLR) at
12 months
Multicenter, superiority
STEMI
Superiority not shown
18 months
CoCr-EES vs. SES
(224:226)
In-segment LL at 9 months
Multicenter, non-inferiority
Long lesion (≥ 25 mm)
1 year
Naples-Diabetes
SES vs. PES vs. ZES-E
(76:75:75)
MACE (death, MI, TVR) at 3 years
Single-center, pilot study
Diabetes
CoCr-EES not non-inferior to
SES (SES superior to CoCrEES)
ZES-E inferior to SES, PES
PLATINUM
CoCr-EES vs. PtCr-EES
(762:768)
TLF at 12 months
Multicenter, non-inferiority
Stable or unstable angina
PtCr-EES non-inferior to CoCrEES
3 years
SES vs. PES
(152:149)
QCA and IVUS parameters
Multicenter, superiority
de novo lesion
SES superior to PES
5 years
Phase I: SES vs. ZES-E
(51:46)
Phase II: SES vs. ZES-R
(103:104)
In-segment LL at 8 months
Multicenter, superiority
Chronic total occlusion
SES superior to ZES-E
1 year
SES vs. BMS
(30:30)
MACE (death, MI, TVR) at 9
months
Single-center, pilot trial
Bifurcation (provisional stenting)
SES similar to BMS
9 months
ZEST
Published in 2011
ESSENCE-DIABETES
KOMER
LONG-DES-III
POET
PRISON III
(abstract only)
PROSUMER
3 years
SEA-SIDE
SES vs. CoCr-EES
(75:75)
Procedural and angiographic
results
Single-center, superiority
Bifurcated lesions
CoCr-EES similar to SES
18 months
ZES-E vs. SES
(80:80)
in-segment binary restenosis rate
at 9-month
Multicenter, non-inferiority
Chronic total occlusion
ZES-E is non-inferior to SES
1 year
BP-BES vs. BMS
(575:582)
MACE (cardiac death, MI, TLR) at
1 year
Multicenter, superiority
AMI
BP-BES superior to BMS
1 year
ZES-R vs. CoCr-EES
(22:22)
% strut coverage (OCT) at 9
months
Multicenter, superiority
de novo lesions
ZES-R similar to PtCr-EES
9 moths
SES vs. PES (441:466)
MACCE (death, MI, stroke, RR,
bleeding) at 1 year
Single-center, superiority
STEMI
SES superior to BMS
1 year
CoCr-EES vs. BMS
(751:747)
POCE at 1-year
Multicenter, superiority
STEMI
Superiority not shown
1 year
ZES-R vs. CoCr-EES
(324:326)
MACE (death, MI , TLR) at 1 year
Multicenter, non-inferiority
unprotected LMCA
ZES-R non-inferior to CoCrEES
1 year
LONG-DES-IV
ZES-R vs. SES
(250:250)
In-segment LL at 9 months
Multicenter, non-inferiority
Long lesion (≥ 25 mm)
ZES-R non-inferior to SES
1 year
NOBORI JAPAN
BP-BES vs. SES
(198:137)
TVF at 9 months
Multicenter, non-inferiority
Stable or unstable angina
BP-BES non-inferior to SES
9 months
SES vs. CoCr-EES
(145:148)
MACE (cardiac death, MI, TLR) at
1 year
Single-center, noninferiority
Bifurcation lesions with
provisional SB stenting
SES similar with CoCr-EES
1 year
ZES-E vs. SES
(4357:4352)
Definite or probable ST at 3 years
Multicenter, superiority
All-comer design
ZES-E not superior to SES
3 years
RESET
CoCr-EES vs. SES
(1597:1600)
TLR at 1 year
Multicenter, non-inferiority
All-comer design
CoCr-EES non-inferior to SES
1 year
Sakakibara et al.
SES vs. CoCr-EES
(50:50)
Angiographic binary restenosis at 8
months
Single-center, superiority
Stable angina on maintenance
hemodialysis
CoCr-EES superior to SES
1 year
Published in 2012
CATOS
COMFORTABLE AMI
COVER OCT
DEBATER
EXAMINATION
ISAR-LEFT MAIN 2
(abstract only)
Pan et al
PROTECT
SEZE
ZES-E vs. SES
(60:61)
In-stent LL at 9 month
Multicenter, superiority
STEMI
ZES-E inferior to SES
1 year
Song et al
SES vs. CoCr-EES
(32:34)
In-segment LL at 9 months
Multicenter, superiority
ISR of DES with diffuse lesion
(>10 mm)
CoC-EES similar with SES
1 year
SORT OUT IV
CoCr-EES vs. SES
(1390:1384)
Composite of cardiac death, MI,
definite ST, TVR at 18 months
Multicenter, non-inferiority
All-comer design
CoCr-EES non-inferior to SES
2 years
SPIRIT V Diabetic
CoCr-EES vs. PES
(218:106)
in-stent LL at 9 months
Multicenter, non-inferiority
and superiority
Diabetes
CoCr-EES non-inferior &
superior to PES
1 year
ZES-R vs. CoCr-EES
(697:694)
TVF at 1 year
Single-center, noninferiority
Stable or unstable angina,
NSTEMI
ZES-R non-inferior to CoCrEES
2 years
X-AMI
CoCr-EES vs. SES
(404:221)
MACE (cardiac death, MI, TVR) at
12 months
Multicenter, non-inferiority
AMI
CoCr-EES non-inferior &
superior to SES
1 year
XIMA
(abstract only)
BMS vs. CoCr-EES
(401:399)
Composite of death, MI, CVA, TVR,
haemorrhage at 1 year
Multicenter, superiority
Octarians (age≥80)
CoCr-EES not superior
(similar) to BMS
1 year
SES vs. CoCr-EES
(101:106)
In-stent LL at 9-month
Multicenter, non-inferiority
Chronic total occlusion
CoCr-EES non-inferior to SES
1 year
COMPARE II
BP-BES vs. CoCr-EES
(1795:912)
Composite cardiac death, MI, TVR
at 12 months
Multicenter, non-inferiority
All-comer design
BES non-inferior to SES
1 year
COVER OCT II
ZES-R vs. CoCr-EES
(20:20)
% strut coverage (OCT) at 3
months
Multicenter, superiority
Stable or unstable angina
ZES-R similar to CoCr-EES
3 months
HOST-ASSURE
(abstract only)
PtCr-EES vs. ZES-R
(2503:1252)
TLF
Multicenter, non-inferiority
All-comer design
PtCr-EES non-inferior to ZESR
1 year
NEXT
(abstract only)
BP-BES vs. CoCr-EES
(1617:1618)
TLR at 1 year
Multicenter, non-inferiority
All-comer design
BP-BES non-inferior to CoCrEES
1 year
BP-BES vs. SES
(1229:1239)
composite of cardiac death, MI,
definite ST, TVR at 9 months
Multicenter, non-inferiority
All-comer design
BP-BES not non-inferior to
SES
1 year
TWENTE
Published in 2013
CIBELES
SORT OUT V
BMS denotes bare metal stents; PES, paclitaxel-eluting stents; SES, sirolimus-eluting stents; ZES-E, Endeavor zotarolimus-eluting stents; CoCr-EES, Cobalt-chromium everolimus-eluting
stents; PtCr-EES, Platinum-chromium everolimus-eluting stents; ZES-R: Resolute zotarolimus-eluting stents; BP-BES, biodegradable polymer biolimus-eluting stents; MACE, major adverse
cardiac events; TVF, target vessel failure; TLF, target lesions failure; MI, myocardial infarction; TVR, target vessel revacularization; TLR, target lesion revascularization; ST, stent thrombosis;
MLD, minimum luminal diameter; LL, late loss; NIH, neointimal hyperplasia; IVUS, intravascular ultrasound; ACS, acute coronary syndrome; NSTEMI, non ST-segment elevation MI; STEMI,
ST-segment elevation MI; LMCA, left main coronary artery; ISR, in-stent restenosis
Supplementary Table S3. Patient Characteristics of Included Trials
Trials
Published in 2002
1. RAVEL1-3
Published in 2003
2. ASPECT4
3. E-SIRIUS5, 6
4. SIRIUS7-10
5. TAXUS I11-13
6. TAXUS II13-15
Published in 2004
7. C-SIRIUS16
8. SES-SMART17, 18
9. TAXUS IV13, 19, 20
Published in 2005
10. BASKET21-23
11 DIABETES24-28
12. ISAR-DESIRE29, 30
13. ISAR-DIABETES30, 31
14. Pache et al.32
15. SIRTAX33-35
16. SPIRIT FIRST36-39
17. STEALTH40
18. STRATEGY41-44
19. TAXi45, 46
20. TAXUS V13, 47
21. TAXUS VI48-52
Published in 2006
22. Cervinka et al.53
23. ENDEAVOR II54-58
Mean Male Diabetes
Age (%)
(%)
Antiplatelet Regimen
Mandatory
Follow-Up Angiography
19
DAPT ≥8 weeks
Yes
76
20
Yes
62
62
65
60
71
71
89
79
23
26
18
16
DAPT ≥1 month (2 centers)
≥6 months (1 center)
DAPT ≥2 months
DAPT ≥3 months
DAPT ≥6 months
DAPT ≥6 months
50:50
129:128
652:662
60
64
62
68
72
72
24
25
24
DAPT ≥2 months
DAPT ≥2 months
DAPT ≥6 months
Yes
Yes
Yes
SES vs. PES
SES vs. BMS
SES vs. PES
PES vs. SES
SES vs. BMS
SES vs. PES
264:281
80:80
100:100
125:125
250:250
503:509
64
67
64
68
67
62
79
63
79
73
78
77
19
100
29
100
31
20
DAPT for 6 months
DAPT ≥12 months
DAPT ≥6 months
DAPT ≥6 months
DAPT ≥6 months
DAPT ≥12 months
CoCr-EES vs. BMS
BP-BES vs. BMS
BMS vs. SES
PES vs. SES
PES vs. BMS
PES vs. BMS
28:32
80:40
88:87
100:102
586:586
219:227
63
62
62
64
63
63
73
71
67
81
70
76
11
25
15
34
31
22
DAPT ≥3 months
DAPT ≥3 months
DAPT ≥3 months
DAPT for 2-12 months
DAPT ≥6 months
DAPT ≥6 months
No
Yes
Yes
Yes
Yes
Partially yes: angiographic substudy
(1/2 of patients)
Yes
Yes
Yes
No
Yes
Yes
SES vs. PES
ZES-E vs. BMS
37:33
598:599
56
62
73
76
36
20
DAPT for 6 months
DAPT ≥3 months
Yes
Partially yes: angiographic follow-up
Stent Comparison
Sample Size
SES vs. BMS
120:118
61
76
PES vs. BMS
118:59
59
SES vs. BMS
SES vs. BMS
PES vs. BMS
BMS vs. PES
175:177
533:525
31:30
270:266
SES vs. BMS
SES vs. BMS
BMS vs. PES
Yes
Yes
Yes
Yes
24. ENDEAVOR III59-61
25. HAAMU-STENT62
(from other work63)
26. ISAR-SMART 330, 64
27. LONG-DES-II65
subgroup (1/2 of patients)
Yes
Yes
ZES-E vs. SES
BMS vs. PES
323:113
82:82
61
63
69
72
29
15
DAPT ≥6 months
DAPT for 12 months
PES vs. SES
SES vs. PES
180:180
250:250
67
61
72
64
0
33
Yes
Yes
28. Pasceri et al.66
(from other works63, 67)
29. PASSION68-70
SES vs. BMS
32:33
62
74
23
DAPT ≥6 months
DAPT ≥ 6 months;
Cilostazol randomized
(2-by-2 factorial design)
Insufficient information
PES vs. BMS
310:309
61
74
31
DAPT ≥6 months
No
30. PRISON II71-74
BMS vs. SES
100:100
59
80
14
DAPT ≥6 months
Yes
31. REALITY75, 76
SES vs. PES
684:669
62
73
28
Yes
32. RRISC77, 78
33. SCANDSTENT79
34. TYPHOON80, 81
BMS vs. SES
SES vs. BMS
SES vs. BMS
37:38
163:159
355:357
73
63
59
89
77
78
14
18
16
DAPT ≥6 months for PES
≥ 2 months for SES
DAPT ≥2 months
DAPT ≥12 months
DAPT ≥6 months
BMS vs. SES
60:60
48
79
28
SES vs. BMS
54:29
60
68
BMS vs. PES
BP-BES vs. PES
BMS vs. SES
SES vs. PES
SES vs. PES
SES vs. BMS
PES vs. BMS
SES vs. BMS
SES vs. BMS
50:53
85:35
52:52
103:102
51:50
98:102
40:40
160:160
39:40
62
64
66
62
63
66
61
63
58
SES vs. PES
200:200
61
Published in 2007
35. de la Llera et al.82
(from other works63, 67)
36. DECODE83
37. Erglis et al84, 85
38. NOBORI 1 - Phase 186, 87
39. Ortolani et al.88
40. Pan et al. (2007)89
41. Petronio et al.90
42. SCORPIUS91, 92
43. SELECTION93
44. SESAMI94-96
45. Strozzi et al.97
Published in 2008
46. DES-DIABETES98-100
No
Yes
Yes
Partially yes: follow-up angiographic
substudy (1/4 of patients)
100
DAPT ≥1 month for BMS
≥9 months for SES
DAPT ≥3 months
No
Yes
83
68
76
82
35
64
80
80
79
12
20
16
37
25
100
13
20
32
DAPT ≥6 months
DAPT ≥ 6 months
DAPT ≥3 months
DAPT ≥12 months
DAPT ≥6 months
DAPT ≥6 months
DAPT ≥9 months
DAPT ≥12 months
DAPT ≥6 months
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
58
100
DAT ≥6 month
Yes
DESSERT101
47.
48. Hong et al.102, 103
49. LEADERS104-109
50. Li et al. (2008)110
51. MISSION!111-113
52. MULTI-STRATEGY114-116
53. PROSIT117, 118
54. SORT OUT II119
55. SPIRIT III120-123
Published in 2009
56. HORIZONS-AMI124-126
57. ISAR-LEFT-MAIN127
58. ISAR-TEST-2128, 129
59. ISAR-TEST-4130, 131
60. Juwana et al.132
61. Li et al. (2009)133
62. NOBORI 1 - Phase 2134
63. PASEO135, 136
64. SOS137, 138
65. SPIRIT II120, 139-142
66. ZEST-AMI143
Published in 2010
67. BASKET-PROVE144, 145
68. COMPARE146, 147
69. ENDEAVOR IV148-150
70 GISSOC II-GISE151
71. GRACIA-3152
72. ISAR-DESIRE 2153
73. OCTAMI154
74. RESOULTE All Comers155, 156
BMS vs. SES
SES vs. PES
BP-BES vs. SES
75:75
85:84
857:850
70
62
64
56
74
75
100
100
24
randomly allocated to TAPT and DAPT
DAPT ≥2 months for BMS, ≥6 months SES
DAPT ≥6 months
DAPT ≥12 months
SES vs. BMS
SES vs. BMS
BMS vs. SES
SES vs. PES
SES vs. PES
24:24
158:152
372:372
154:154
1065:1033
47
59
64
60
64
73
78
76
76
75
13
10
14
25
15
DAPT ≥6 months
DAPT ≥12 months
DAPT ≥3 months
DAPT ≥6 months
DAPT ≥12 months
CoCr-EES vs. PES
669:333
63
70
28
DAPT ≥6 months
PES vs. BMS
PES vs. SES
SES vs. ZES-E
CoCr-EES vs. SES
SES vs. PES
SES vs. PES
BP-BES vs. PES
BMS vs. PES vs. SES
BMS vs. PES
2257:749
302:305
335:339
652:652
196:201
16:16
153:90
90:90:90
39:41
60
69
67
67
61
51
63
62
67
77
78
23
76
82
78
72
71
100
16
29
27
29
9
13
21
26
44
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
CoCr-EES vs. PES
ZES-E vs. SES vs. PES
223:77
108:110:110
62
60
73
83
23
26
DAPT ≥6 months
DAPT indefinitely
DAPT ≥6 months
DAPT ≥6 month
DAPT ≥6 months
DAPT ≥9 months
DAPT ≥6 months
DAPT ≥6 months
DAPT ≥6 months for PES
≥1 month for BMS
DAPT ≥6 months
DAPT ≥12 months.
775:774:765
897:903
773:775
66
63
64
76
69
68
16
17
31
DAPT ≥12 months
DAPT ≥12 months
DAPT ≥6 months
78:74
216:217
225:225
33:11
1140:1152
64
61
67
61
64
83
83
77
77
77
22
18
36
14
23
DAPT ≥6 months
DAPT ≥12 months
DAPT ≥6 months
DAPT ≥6 months
DAPT ≥6 months
No
No
Partially yes: angiographic follow-up
subgroup (1/5 of patients)
Yes
Yes
Yes
Yes
Partially yes: angiographic follow-up
SES vs. CoCr-EES vs. BMS
CoCr-EES vs. PES
ZES-E vs. PES
BMS vs. SES
BMS vs. PES
SES vs. PES
ZES-E vs. BMS
ZES-R vs. CoCr-EES
Yes
Yes
Partially yes: angiographic follow-up
subgroup (1/4 of patients)
Yes
Yes
No
Yes
Partially yes: angiographic follow-up
subgroup (0.5% of patients)
Partially yes: angiographic follow-up
cohort (1/2 of patients)
Yes
Yes
75. SORT OUT III157, 158
76. SPIRIT IV122, 159, 160
77. ZEST161, 162
Published in 2011
78. ESSENCE-DIABETES163
79. EXCELLENT164, 165
80. GARA-GARA166
81. KOMER167
80. LONG-DES-III168
83. Naples-Diabetes169
84. PLATINUM170
85. POET171
86. PRISON III172, 173
87. PROSUMER174
88. SEA-SIDE175
Published in 2012
89. CATOS176
90. COMFORTABLE AMI177, 178
91. COVER OCT179
92. DEBATER180
subgroup (1/5 of patients)
No
No
Yes
ZES-E vs. SES
CoCr-EES vs. PES
ZES-E vs. SES vs. PES
1162:1170
2458:1229
883:878:884
64
63
62
73
68
66
13
32
29
DAPT ≥12 months
DAPT ≥6 months
DAPT ≥12 months
CoCr-EES vs. SES
CoCr-EES vs. SES
SES vs. PES
ZES-E vs. SES vs. PES
CoCr-EES vs. SES
SES vs. PES vs. ZES-E
CoCr-EES vs. PtCr-EES
SES vs. PES
149:151
1079:364
400:400
205:204:202
224:226
76:75:75
762:768
152:149
63
63
69
60
63
64
64
62
59
65
71
79
70
57
71
36
100
38
46
21
30
100
24
30
Yes
Yes
Yes
Yes
Yes
No
No
Yes
51:46
30:30
75:75
62
62
65
84
23
80
28
DAPT ≥12 months
Randomized to 6- vs. 12-months DAPT (1:1)
DAPT ≥6 months
DAPT ≥12 months
DAPT ≥12 months
DAPT ≥6 months
DAPT ≥6 months
DAPT ≥6 months for PES
≥3 months for SES
DAPT ≥12 months
Insufficient information
DAPT ≥12 months
80:80
575:582
22:22
441:466
63
61
59
60
71
79
70
76
32
15
34
10
Yes
No
Yes
No
SES vs. ZES-E
SES vs. BMS
SES vs. CoCr-EES
ZES-E vs. SES
BP-BES vs. BMS
ZES-R vs. CoCr-EES
SES vs. PES
93. EXAMINATION181, 182
94. ISAR-LEFT MAIN 2183
95. LONG-DES-IV184
96. NOBORI JAPAN185
97. Pan et al. (2012) 186
98. PROTECT187, 188
99. RESET189
CoCr-EES vs. BMS
ZES-R vs. CoCr-EES
ZES-R vs. SES
BP-BES vs. SES
SES vs. CoCr-EES
ZES-E vs. SES
CoCr-EES vs. SES
751:747
324:326
250:250
198:137
145:148
4357:4352
1597:1600
61
70
63
67
63
62
69
84
75
73
72
80
76
77
18
29
29
39
32
28
45
DAPT ≥12 months
DAPT ≥12 months
DAPT ≥9 months
DAPT ≥ 6-12 months for SES
≥ 1 month for BMS
DAPT ≥12 months
DAPT ≥12 months
DAPT ≥12 months
DAPT ≥3 months
DAPT ≥12 months
DAPT 3-12 months
DAPT ≥ 3 months
100. Sakakibara et al.190
101. SEZE191
102. Song et al.192
103. SORT OUT IV193-195
SES vs. CoCr-EES
ZES-E vs. SES
SES vs. CoCr-EES
CoCr-EES vs. SES
50:50
60:61
32:34
1390:1384
66
61
63
64
70
81
52
76
70
22
30
14
DAPT ≥12 months
DAPT ≥12 months
DAPT ≥6 months
DAPT ≥12 months
Yes
Yes
No
No
Yes
Yes
Yes
No
No
Partially yes: angiographic substudy
(1/6 of patients)
Yes
Yes
Yes
No
104. SPIRIT V Diabetic Study196
105. TWENTE197-199
106. X-AMI200
107. XIMA201
Published in 2013
108. CIBELLES202, 203
109. COMPARE II204
110. COVER OCT II205
111. HOST-ASSURE206, 207
112. NEXT208
113. SORT OUT V209
CoCr-EES vs. PES
ZES-R vs. CoCr-EES
CoCr-EES vs. SES
BMS vs. CoCr-EES
218:106
697:694
404:221
401:399
65
64
61
83
70
72
74
60
100
22
10
25
DAPT ≥6 months
DAPT ≥12 months
DAPT ≥12 months
DAPT ≥12 months for EES
≥1 month for BMS
Yes
No
No
No
SES vs. CoCr-EES
BP-BES vs. CoCr-EES
ZES-R vs. CoCr-EES
PtCr-EES vs. ZES-R
101:106
1795:912
20:20
2503:1252
64
63
64
63
84
74
68
68
36
22
38
32
Yes
No
Yes
No
BP-BES vs. CoCr-EES
1617:1618
69
77
46
DAPT ≥9 months
DAPT ≥12 months
DAPT ≥ 3 months
DAPT ≥12 months
randomized to DDAT vs. TAT (1:1)
unclear
BP-BES vs. SES
1229:1239
65
75
15
DAPT ≥12 months
Partially yes: angiographic substudy
(1/4 of patients)
No
BMS denotes bare metal stents; PES, paclitaxel-eluting stents; SES, sirolimus-eluting stents; ZES-E, Endeavor zotarolimus-eluting stents; CoCr-EES, Cobalt-chromium everolimus-eluting
stents; PtCr-EES, Platinum-chromium everolimus-eluting stents; ZES-R: Resolute zotarolimus-eluting stents; BP-BES, biodegradable polymer biolimus-eluting stents; DAPT, dual
antiplatelet therapy; DDAT, douuble-dose dual antiplatelet therapy; TAT, triple antiplatelet therapy
Supplement Table S4. Sensitivity Analysis of Definite or Probable Stent Thrombosis
Within 1 Year
Comparison
BMS as reference
BMS vs. BMS
PES vs. BMS
ZES-E vs. BMS
BP-BES vs. BMS
SES vs. BMS
ZES-R vs. BMS
CoCr-EES vs. BMS
PtCr-EES vs. BMS
PES as reference
BMS vs. PES
PES vs. PES
ZES-E vs. PES
BP-BES vs. PES
SES vs. PES
ZES-R vs. PES
CoCr-EES vs. PES
PtCr-EES vs. PES
ZES-E as reference
BMS vs. ZES-E
PES vs. ZES-E
ZES-E vs. ZES-E
BP-BES vs. ZES-E
SES vs. ZES-E
ZES-R vs. ZES-E
CoCr-EES vs. ZES-E
PtCr-EES vs. ZES-E
BP-BES as reference
BMS vs. BP-BES
PES vs. BP-BES
ZES-E vs. BP-BES
BP-BES vs. BP-BES
SES vs. BP-BES
ZES-R vs. BP-BES
CoCr-EES vs. BP-BES
PtCr-EES vs. BP-BES
SES as reference
BMS vs. SES
PES vs. SES
ZES-E vs. SES
BP-BES vs. SES
SES vs. SES
ZES-R vs. SES
CoCr-EES vs. SES
PtCr-EES vs. SES
ZES-R as reference
BMS vs. ZES-R
PES vs. ZES-R
ZES-E vs. ZES-R
All trials
Low risk of bias
Excluding studies
with diabetes
Excluding studies
with STEMI
0.85 (0.60-1.19)
0.75 (0.45-1.19)
0.55 (0.32-0.89)
0.53 (0.39-0.73)
0.52 (0.24-1.18)
0.35 (0.23-0.52)
0.31 (0.10-0.89)
0.87 (0.59-1.32)
0.95 (0.54-1.74)
0.54 (0.30-0.91)
0.54 (0.36-0.80)
0.51 (0.21-1.22)
0.34 (0.21-0.53)
0.30 (0.09-0.95)
0.84 (0.60-1.20)
0.74 (0.44-1.18)
0.54 (0.31-0.88)
0.53 (0.38-0.74)
0.52 (0.24-1.14)
0.35 (0.22-0.52)
0.31 (0.10-0.91)
0.89 (0.48-1.65)
0.83 (0.41-1.68)
0.49 (0.24-0.92)
0.47 (0.28-0.78)
0.48 (0.17-1.21)
0.31 (0.17-0.57)
0.28 (0.07-1.03)
1.17 (0.84-1.67)
0.88 (0.54-1.42)
0.64 (0.37-1.08)
0.63 (0.46-0.87)
0.61 (0.29-1.34)
0.40 (0.27-0.60)
0.35 (0.12-1.07)
1.15 (0.76-1.71)
1.09 (0.62-1.98)
0.63 (0.33-1.08)
0.62 (0.41-0.91)
0.59 (0.25-1.38)
0.39 (0.25-0.59)
0.35 (0.10-1.10)
1.19 (0.83-1.68)
0.88 (0.54-1.39)
0.65 (0.37-1.08)
0.63 (0.45-0.88)
0.62 (0.29-1.33)
0.41 (0.27-0.61)
0.37 (0.12-1.09)
1.13 (0.60-2.07)
0.93 (0.48-1.82)
0.55 (0.25-1.07)
0.53 (0.32-0.86)
0.54 (0.20-1.28)
0.35 (0.20-0.58)
0.32 (0.08-1.09)
1.33 (0.84-2.21)
1.14 (0.70-1.84)
0.73 (0.40-1.33)
0.70 (0.48-1.10)
0.70 (0.30-1.66)
0.46 (0.27-0.78)
0.40 (0.13-1.28)
1.05 (0.57-1.86)
0.92 (0.51-1.61)
0.57 (0.26-1.11)
0.57 (0.33-0.94)
0.54 (0.19-1.44)
0.36 (0.18-0.66)
0.32 (0.08-1.08)
1.35 (0.85-2.26)
1.13 (0.72-1.86)
1.00 (1.00-1.00)
0.72 (0.48-1.11)
0.73 (0.39-1.34)
0.42 (0.13-1.30)
0.70 (0.31-1.67)
1.21 (0.59-2.43)
1.08 (0.55-2.10)
1.00 (1.00-1.00)
0.57 (0.31-1.01)
0.59 (0.25-1.24)
0.34 (0.08-1.26)
0.58 (0.20-1.54)
1.83 (1.12-3.08)
1.56 (0.93-2.69)
1.36 (0.75-2.53)
0.98 (0.60-1.59)
0.97 (0.40-2.23)
0.63 (0.37-1.07)
0.55 (0.18-1.76)
1.84 (1.10-3.37)
1.60 (0.93-3.01)
1.74 (0.90-3.80)
1.00 (0.61-1.71)
0.94 (0.38-2.48)
0.63 (0.36-1.13)
0.56 (0.16-1.89)
1.85 (1.14-3.22)
1.55 (0.93-2.73)
1.36 (0.75-2.59)
0.98 (0.63-1.62)
0.97 (0.41-2.27)
0.64 (0.38-1.10)
0.58 (0.18-1.78)
2.04 (1.09-4.23)
1.82 (0.94-3.95)
1.69 (0.81-4.07)
0.97 (0.56-1.85)
0.97 (0.36-2.65)
0.64 (0.34-1.27)
0.57 (0.16-2.21)
1.88 (1.37-2.58)
1.60 (1.14-2.18)
1.42 (0.91-2.08)
1.03 (0.63-1.67)
0.98 (0.46-2.20)
0.65 (0.45-0.93)
0.57 (0.19-1.66)
1.84 (1.25-2.77)
1.60 (1.09-2.41)
1.75 (1.06-3.07)
1.00 (0.59-1.64)
0.94 (0.41-2.21)
0.63 (0.42-0.94)
0.55 (0.17-1.75)
1.88 (1.36-2.64)
1.58 (1.13-2.21)
1.39 (0.90-2.10)
1.02 (0.62-1.60)
0.98 (0.46-2.09)
0.65 (0.45-0.93)
0.59 (0.18-1.67)
2.11 (1.28-3.55)
1.88 (1.16-3.15)
1.74 (0.99-3.21)
1.03 (0.54-1.79)
1.01 (0.41-2.36)
0.66 (0.42-1.03)
0.59 (0.17-2.01)
1.91 (0.85-4.13)
1.64 (0.75-3.48)
1.42 (0.60-3.31)
1.94 (0.82-4.74)
1.70 (0.73-4.08)
1.85 (0.70-5.29)
1.92 (0.88-4.22)
1.62 (0.75-3.48)
1.42 (0.60-3.28)
2.09 (0.83-5.81)
1.86 (0.78-4.92)
1.73 (0.65-5.11)
BP-BES vs. ZES-R
SES vs. ZES-R
ZES-R vs. ZES-R
CoCr-EES vs. ZES-R
PtCr-EES vs. ZES-R
CoCr-EES as reference
BMS vs. CoCr-EES
PES vs. CoCr-EES
ZES-E vs. CoCr-EES
BP-BES vs. CoCr-EES
SES vs. CoCr-EES
ZES-R vs. CoCr-EES
CoCr-EES vs. CoCr-EES
PtCr-EES vs. CoCr-EES
PtCr-EES as reference
BMS vs. PtCr-EES
PES vs. PtCr-EES
ZES-E vs. PtCr-EES
BP-BES vs. PtCr-EES
SES vs. PtCr-EES
ZES-R vs. PtCr-EES
CoCr-EES vs. PtCr-EES
PtCr-EES vs. PtCr-EES
1.04 (0.45-2.48)
1.02 (0.45-2.15)
0.66 (0.35-1.25)
0.57 (0.23-1.47)
1.06 (0.40-2.62)
1.07 (0.45-2.45)
0.67 (0.31-1.38)
0.58 (0.22-1.59)
1.04 (0.44-2.45)
1.02 (0.48-2.19)
0.66 (0.34-1.26)
0.59 (0.23-1.48)
1.03 (0.38-2.75)
0.99 (0.42-2.47)
0.66 (0.31-1.43)
0.59 (0.20-1.76)
2.90 (1.91-4.38)
2.47 (1.68-3.66)
2.17 (1.28-3.69)
1.58 (0.93-2.69)
1.55 (1.07-2.22)
1.52 (0.80-2.88)
0.87 (0.31-2.43)
2.93 (1.89-4.74)
2.56 (1.69-4.03)
2.78 (1.53-5.45)
1.59 (0.89-2.76)
1.60 (1.06-2.39)
1.50 (0.72-3.22)
0.88 (0.29-2.62)
2.89 (1.93-4.46)
2.45 (1.65-3.68)
2.15 (1.26-3.61)
1.56 (0.91-2.64)
1.54 (1.08-2.23)
1.51 (0.80-2.96)
0.90 (0.31-2.51)
3.19 (1.75-6.04)
2.84 (1.72-4.95)
2.62 (1.36-5.49)
1.56 (0.79-2.93)
1.51 (0.97-2.39)
1.52 (0.70-3.18)
0.89 (0.27-2.88)
2.69 (0.97-6.93)
2.49 (0.87-6.46)
2.04 (0.74-5.19)
1.72 (0.60-4.66)
1.54 (0.65-3.63)
1.49 (0.50-3.94)
1.03 (0.39-2.52)
-
3.31 (1.05-11.05)
2.90 (0.91-9.60)
3.16 (0.93-12.16)
1.80 (0.53-6.12)
1.80 (0.57-5.81)
1.71 (0.63-4.58)
1.14 (0.38-3.39)
-
3.20 (1.10-9.99)
2.68 (0.92-8.23)
2.37 (0.77-7.88)
1.73 (0.56-5.65)
1.69 (0.60-5.47)
1.68 (0.67-4.38)
1.11 (0.40-3.24)
-
3.56 (0.97-13.65)
3.17 (0.92-11.78)
2.94 (0.79-11.87)
1.75 (0.45-6.42)
1.68 (0.50-6.00)
1.70 (0.57-5.01)
1.12 (0.35-3.66)
-
BMS denotes bare metal stents; PES, paclitaxel-eluting stents; SES, sirolimus-eluting stents; ZES-E, Endeavor zotarolimuseluting stents; CoCr-EES, Cobalt-chromium everolimus-eluting stents; PtCr-EES, Platinum-chromium everolimus-eluting
stents; ZES-R: Resolute zotarolimus-eluting stents; BP-BES, biodegradable polymer biolimus-eluting stents; STEMI, STsegment elevation myocardial infarction
Supplement Figure S1. Risk of Bias Assessment Summary
Risk of bias of each included trial was assessed with the Cochrane Collaboration’s tool. This ‘risk of bias summary’ figure
presents all of the judgements in a cross-tabulation of study by entry. Green represents ‘Yes (low risk of bias)’; yellow,
‘Unclear’; red, ‘No (high risk of bias)’.
Supplement Figure S2. Ranks for Study Stents Regarding Definite or Probable
Stent Thrombosis
(A) Rankograms for the study stents. On the horizontal axis are the 8 possible ranks and on the vertical axis the probability
of a treatment to achieve each rank.
(B) Barplots for the ranking probabilities of competing stents. On the horizontal axis is the possible rank of each treatment
(from best to worse according to the outcome). The size of each bar corresponds to the probability of each treatment to be
at a specific rank.
% probability to rank at each place
BMS
PES
SES
ZES-E
2
3
CoCr-EES
PtCr-EES
ZES-R
BP-BES
100%
80%
60%
40%
20%
0%
1
4
Ranks
5
6
7
8
Supplement Figure S3. Definite or Probable Stent Thrombosis at the Longest
Follow-Up Available
The squares and horizontal lines indicate pairwise odds ratios and their 95% credible intervals for definite or probable stent
thrombosis at the longest follow-up available estimated with multiple-treatment meta-analysis.
BMS denotes bare metal stents; PES, paclitaxel-eluting stents; SES, sirolimus-eluting stents; ZES-E, Endeavor zotarolimuseluting stents; CoCr-EES, Cobalt-chromium everolimus-eluting stents; PtCr-EES, Platinum-chromium everolimus-eluting
stents; ZES-R: Resolute zotarolimus-eluting stents; BP-BES, biodegradable polymer biolimus-eluting stents
Supplement Figure S4. Definite or Probable Stent Thrombosis, Early (≤30 days)
The squares and horizontal lines indicate pairwise odds ratios and their 95% credible intervals for early definite or probable
stent thrombosis within 30 days estimated with multiple-treatment meta-analysis.
BMS denotes bare metal stents; PES, paclitaxel-eluting stents; SES, sirolimus-eluting stents; ZES-E, Endeavor zotarolimuseluting stents; CoCr-EES, Cobalt-chromium everolimus-eluting stents; PtCr-EES, Platinum-chromium everolimus-eluting
stents; ZES-R: Resolute zotarolimus-eluting stents; BP-BES, biodegradable polymer biolimus-eluting stents
Supplement Figure S5. Definite or Probable Stent Thrombosis, Late (31-365 days)
The squares and horizontal lines indicate pairwise odds ratios and their 95% credible intervals for late definite or probable
stent thrombosis (31-365 days) estimated with multiple-treatment meta-analysis.
BMS denotes bare metal stents; PES, paclitaxel-eluting stents; SES, sirolimus-eluting stents; ZES-E, Endeavor zotarolimuseluting stents; CoCr-EES, Cobalt-chromium everolimus-eluting stents; PtCr-EES, Platinum-chromium everolimus-eluting
stents; ZES-R: Resolute zotarolimus-eluting stents; BP-BES, biodegradable polymer biolimus-eluting stents
Supplement Figure S6. Definite or Probable Stent Thrombosis, Very Late (>365
days)
The squares and horizontal lines indicate pairwise odds ratios and their 95% credible intervals for very late definite or
probable stent thrombosis (>365 days) estimated with multiple-treatment meta-analysis.
BMS denotes bare metal stents; PES, paclitaxel-eluting stents; SES, sirolimus-eluting stents; ZES-E, Endeavor zotarolimuseluting stents; CoCr-EES, Cobalt-chromium everolimus-eluting stents; PtCr-EES, Platinum-chromium everolimus-eluting
stents; ZES-R: Resolute zotarolimus-eluting stents; BP-BES, biodegradable polymer biolimus-eluting stents
Supplement Figure S7. Definite or Probable Stent Thrombosis, Late and Very Late
(>30 days)
The squares and horizontal lines indicate pairwise odds ratios and their 95% credible intervals for late and very late definite
or probable stent thrombosis (>30 days) estimated with multiple-treatment meta-analysis.
BMS denotes bare metal stents; PES, paclitaxel-eluting stents; SES, sirolimus-eluting stents; ZES-E, Endeavor zotarolimuseluting stents; CoCr-EES, Cobalt-chromium everolimus-eluting stents; PtCr-EES, Platinum-chromium everolimus-eluting
stents; ZES-R: Resolute zotarolimus-eluting stents; BP-BES, biodegradable polymer biolimus-eluting stents
Supplement Figure S8. Definite Stent Thrombosis (ST) with Reference to Bare Metal Stent
The squares and horizontal lines indicate odds ratios and their 95% credible intervals for definite or probable stent thrombosis estimated with multiple-treatment meta-analysis. All
comparisons are presented with reference to bare metal stent.
ST denotes stent thrombosis; BMS, bare metal stents; PES, paclitaxel-eluting stents; SES, sirolimus-eluting stents; ZES-E, Endeavor zotarolimus-eluting stents; CoCr-EES, Cobaltchromium everolimus-eluting stents; PtCr-EES, Platinum-chromium everolimus-eluting stents; ZES-R: Resolute zotarolimus-eluting stents; BP-BES, biodegradable polymer biolimus-eluting
stents
Supplement Figure S9. Inconsistency Plot for Triangular Loops
BMS, bare metal stents; PES, paclitaxel-eluting stents; SES, sirolimus-eluting stents; ZES-E, Endeavor zotarolimus-eluting
stents; CoCr-EES, Cobalt-chromium everolimus-eluting stents; PtCr-EES, Platinum-chromium everolimus-eluting stents;
ZES-R: Resolute zotarolimus-eluting stents; BP-BES, biodegradable polymer biolimus-eluting stents
Supplement Figure S10. Target Vessel Revascularization Within 1 Year
The squares and horizontal lines indicate pairwise odds ratios and their 95% credible intervals for target vessel
revascularization within 1 year estimated with multiple-treatment meta-analysis.
BMS denotes bare metal stents; PES, paclitaxel-eluting stents; SES, sirolimus-eluting stents; ZES-E, Endeavor zotarolimuseluting stents; CoCr-EES, Cobalt-chromium everolimus-eluting stents; PtCr-EES, Platinum-chromium everolimus-eluting
stents; ZES-R: Resolute zotarolimus-eluting stents; BP-BES, biodegradable polymer biolimus-eluting stents
Supplement Figure S11. All-Cause Death Within 1 Year
The squares and horizontal lines indicate pairwise odds ratios and their 95% credible intervals for all-cause death within 1
year estimated with multiple-treatment meta-analysis.
BMS denotes bare metal stents; PES, paclitaxel-eluting stents; SES, sirolimus-eluting stents; ZES-E, Endeavor zotarolimuseluting stents; CoCr-EES, Cobalt-chromium everolimus-eluting stents; PtCr-EES, Platinum-chromium everolimus-eluting
stents; ZES-R: Resolute zotarolimus-eluting stents; BP-BES, biodegradable polymer biolimus-eluting stents
Supplement Figure S12. Cardiac Death Within 1 Year
The squares and horizontal lines indicate pairwise odds ratios and their 95% credible intervals for cardiac death within 1
year estimated with multiple-treatment meta-analysis.
BMS denotes bare metal stents; PES, paclitaxel-eluting stents; SES, sirolimus-eluting stents; ZES-E, Endeavor zotarolimuseluting stents; CoCr-EES, Cobalt-chromium everolimus-eluting stents; PtCr-EES, Platinum-chromium everolimus-eluting
stents; ZES-R: Resolute zotarolimus-eluting stents; BP-BES, biodegradable polymer biolimus-eluting stents
Supplement Figure S13. Network Plot of Sensitivity Analysis for Trials with Low
Risk of Bias
Each stent is represented by a node. The size of the node is proportional to the sample size randomized to each stent, while
the thickness of the line connecting the nodes is to the total randomized sample size in each pairwise treatment comparison.
A total of 48 trials including 60,911 patients were analyzed with exclusion of trials with any potential risk of bias (unclear or
no) in the 6 domains assessed according the Cochrane Collaboration’s tool (random sequence generation, allocation
concealment, blinding of clinical outcome assessment, incomplete outcome data addressed, free of selective reporting, free
of other bias).
BMS denotes bare metal stents; PES, paclitaxel-eluting stents; SES, sirolimus-eluting stents; ZES-E, Endeavor zotarolimuseluting stents; CoCr-EES, Cobalt-chromium everolimus-eluting stents; PtCr-EES, Platinum-chromium everolimus-eluting
stents; ZES-R: Resolute zotarolimus-eluting stents; BP-BES, biodegradable polymer biolimus-eluting stents
Supplement Figure S14. Sensitivity Analysis for Trials with Low Risk of Bias
The squares and horizontal lines indicate pairwise odds ratios and their 95% credible intervals for definite or probable stent
thrombosis within 1 year estimated with multiple-treatment meta-analysis. Gray squares and lines represent the analysis
with all trials included, while red squares and lines do the sensitivity analysis including trials with low risk of bias.
BMS denotes bare metal stents; PES, paclitaxel-eluting stents; SES, sirolimus-eluting stents; ZES-E, Endeavor zotarolimuseluting stents; CoCr-EES, Cobalt-chromium everolimus-eluting stents; PtCr-EES, Platinum-chromium everolimus-eluting
stents; ZES-R: Resolute zotarolimus-eluting stents; BP-BES, biodegradable polymer biolimus-eluting stents
References
1.
Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G,
Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a
standard stent for coronary revascularization. N Engl J Med 2002;346(23):1773-80.
2.
Fajadet J, Morice MC, Bode C, Barragan P, Serruys PW, Wijns W, Constantini CR, Guermonprez JL,
Eltchaninoff H, Blanchard D, Bartorelli A, Laarman GJ, Perin M, Sousa JE, Schuler G, Molnar F, Guagliumi G,
Colombo A, Ban Hayashi E, Wulfert E. Maintenance of long-term clinical benefit with sirolimus-eluting
coronary stents: three-year results of the RAVEL trial. Circulation 2005;111(8):1040-4.
3.
Morice MC, Serruys PW, Barragan P, Bode C, Van Es GA, Stoll HP, Snead D, Mauri L, Cutlip DE,
Sousa E. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL
trial. J Am Coll Cardiol 2007;50(14):1299-304.
4.
Park SJ, Shim WH, Ho DS, Raizner AE, Park SW, Hong MK, Lee CW, Choi D, Jang Y, Lam R,
Weissman NJ, Mintz GS. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med
2003;348(16):1537-45.
5.
Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt G, Investigators
ES. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries:
double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362(9390):1093-9.
6.
Schofer J, Breithardt G, Garcia E, Gershlick AH, Schlüter M, Wichter T, W. Wijns. The European
multicenter, randomized, double-blind study of the Sirolimus-eluting stent in the treatment of patients with de
novo coronary artery lesions (E-SIRIUS): 4-year clinical outcomes.
http://www.crtonline.org/flash.aspx?PAGE_ID=3336.
7.
Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes
DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE, Investigators S. Sirolimus-eluting stents versus standard
stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349(14):1315-23.
8.
Holmes DR, Jr., Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, Brown C, Fischell T, Wong
SC, Midei M, Snead D, Kuntz RE. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial
of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation
2004;109(5):634-40.
9.
Weisz G, Leon MB, Holmes DR, Jr., Kereiakes DJ, Clark MR, Cohen BM, Ellis SG, Coleman P, Hill
C, Shi C, Cutlip DE, Kuntz RE, Moses JW. Two-year outcomes after sirolimus-eluting stent implantation:
results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol
2006;47(7):1350-5.
10.
Weisz G, Leon MB, Holmes DR, Jr., Kereiakes DJ, Popma JJ, Teirstein PS, Cohen SA, Wang H,
Cutlip DE, Moses JW. Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS
(Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. J Am Coll Cardiol 2009;53(17):1488-97.
11.
Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, Russell ME. TAXUS I: sixand twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de
novo coronary lesions. Circulation 2003;107(1):38-42.
12.
Grube E, Silber S, Hauptmann KE, Buellesfeld L, Mueller R, Lim V, Gerckens U, Russell ME. Twoyear-plus follow-up of a paclitaxel-eluting stent in de novo coronary narrowings (TAXUS I). Am J Cardiol
2005;96(1):79-82.
13.
Stone GW, Ellis SG, Colombo A, Grube E, Popma JJ, Uchida T, Bleuit JS, Dawkins KD, Russell ME.
Long-term safety and efficacy of paclitaxel-eluting stents final 5-year analysis from the TAXUS Clinical Trial
Program. JACC Cardiovasc Interv 2011;4(5):530-42.
14.
Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, Dudek D, Fort S, Schiele F,
Zmudka K, Guagliumi G, Russell ME, Group TIS. Randomized study to assess the effectiveness of slow- and
moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation
2003;108(7):788-94.
15.
Silber S, Colombo A, Banning AP, Hauptmann K, Drzewiecki J, Grube E, Dudek D, Baim DS. Final
5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow- and moderaterelease polymer-based paclitaxel-eluting stents for de novo coronary artery lesions. Circulation
2009;120(15):1498-504.
16.
Schampaert E, Cohen EA, Schluter M, Reeves F, Traboulsi M, Title LM, Kuntz RE, Popma JJ,
Investigators CS. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de
novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004;43(6):1110-5.
17.
Ardissino D, Cavallini C, Bramucci E, Indolfi C, Marzocchi A, Manari A, Angeloni G, Carosio G,
Bonizzoni E, Colusso S, Repetto M, Merlini PA, Investigators S-S. Sirolimus-eluting vs uncoated stents for
prevention of restenosis in small coronary arteries: a randomized trial. JAMA 2004;292(22):2727-34.
18.
Menozzi A, Solinas E, Ortolani P, Repetto A, Saia F, Piovaccari G, Manari A, Magagnini E, Vignali L,
Bonizzoni E, Merlini PA, Cavallini C, Ardissino D, Investigators S-S. Twenty-four months clinical outcomes of
sirolimus-eluting stents for the treatment of small coronary arteries: the long-term SES-SMART clinical study.
Eur Heart J 2009;30(17):2095-101.
19.
Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P,
Greenberg J, Popma JJ, Russell ME, Investigators T-I. A polymer-based, paclitaxel-eluting stent in patients with
coronary artery disease. N Engl J Med 2004;350(3):221-31.
20.
Ellis SG, Stone GW, Cox DA, Hermiller J, O'Shaughnessy C, Mann T, Turco M, Caputo R, Bergin PJ,
Bowman TS, Baim DS, Investigators TI. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year
final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a
Single Paclitaxel-Eluting Stent). JACC Cardiovasc Interv 2009;2(12):1248-59.
21.
Kaiser C, Brunner-La Rocca HP, Buser PT, Bonetti PO, Osswald S, Linka A, Bernheim A, Zutter A,
Zellweger M, Grize L, Pfisterer ME. Incremental cost-effectiveness of drug-eluting stents compared with a
third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trial
(BASKET). The Lancet;366(9489):921-929.
22.
Rocca HPB-L, Kaiser C, Bernheim A, Zellweger MJ, Jeger R, Buser PT, Osswald S, Pfisterer M.
Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent
KostenEffektivitäts Trial (BASKET): an 18-month analysis. The Lancet;370(9598):1552-1559.
23.
Schomig A, Dibra A, Windecker S, Mehilli J, Suarez de Lezo J, Kaiser C, Park SJ, Goy JJ, Lee JH, Di
Lorenzo E, Wu J, Juni P, Pfisterer ME, Meier B, Kastrati A. A meta-analysis of 16 randomized trials of
sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll
Cardiol 2007;50(14):1373-80.
24.
Sabaté M, Jiménez-Quevedo P, Angiolillo DJ, Gómez-Hospital JA, Alfonso F, Hernández-Antolín R,
Goicolea J, Bañuelos C, Escaned J, Moreno R, Fernández C, Fernández-Avilés F, Macaya C, Investigators ftD.
Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary
Revascularization in Diabetic Patients: The Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial.
Circulation 2005;112(14):2175-2183.
25.
Jiménez-Quevedo P, Sabaté M, Angiolillo DJ, Alfonso F, Hernández-Antolín R, SanMartín M,
Gómez-Hospital JA, Bañuelos C, Escaned J, Moreno R, Fernández C, Fernández-Avilés F, Macaya C. Longterm clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses:
long-term results of the DIABETES trial. European Heart Journal 2007;28(16):1946-1952.
26.
de Waha A, Dibra A, Kufner S, Baumgart D, Sabate M, Maresta A, Schomig A, Kastrati A. Long-term
outcome after sirolimus-eluting stents versus bare metal stents in patients with diabetes mellitus: a patient-level
meta-analysis of randomized trials. Clin Res Cardiol 2011;100(7):561-70.
27.
Jimenez-Quevedo P, Hernando L, Iniguez A, SanRoman A, Antolin RH, Alfonso F, Banuelos C,
Escaned J, Macaya C, Sabate M. Four years follow-up of DIABETES trial. Journal of the American College of
Cardiology 2009;53(10):A33.
28.
Tuesday, 30 August 2011. European Heart Journal 2011;32(suppl 1):633-933.
29.
Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schuhlen H, Schmitt C,
Dirschinger J, Schomig A, Investigators I-DS. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon
angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled
trial. JAMA 2005;293(2):165-71.
30.
Birkmeier KA, Kastrati A, Byrne RA, Holle H, Schulz S, Tiroch K, Kufner S, Massberg S, Laugwitz
KL, Schomig A, Mehilli J. Five-year clinical outcomes of sirolimus-eluting versus paclitaxel-eluting stents in
high-risk patients. Catheter Cardiovasc Interv 2011;77(4):494-501.
31.
Dibra A, Kastrati A, Mehilli J, Pache J, Schuhlen H, von Beckerath N, Ulm K, Wessely R, Dirschinger
J, Schomig A, Investigators I-DS. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic
patients. N Engl J Med 2005;353(7):663-70.
32.
Pache J, Dibra A, Mehilli J, Dirschinger J, Schomig A, Kastrati A. Drug-eluting stents compared with
thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. Eur Heart J
2005;26(13):1262-8.
33.
Windecker S, Remondino A, Eberli FR, Juni P, Raber L, Wenaweser P, Togni M, Billinger M, Tuller D,
Seiler C, Roffi M, Corti R, Sutsch G, Maier W, Luscher T, Hess OM, Egger M, Meier B. Sirolimus-eluting and
paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005;353(7):653-62.
34.
Billinger M, Beutler J, Taghetchian KR, Remondino A, Wenaweser P, Cook S, Togni M, Seiler C,
Stettler C, Eberli FR, Luscher TF, Wandel S, Juni P, Meier B, Windecker S. Two-year clinical outcome after
implantation of sirolimus-eluting and paclitaxel-eluting stents in diabetic patients. Eur Heart J 2008;29(6):718-
25.
35.
Raber L, Wohlwend L, Wigger M, Togni M, Wandel S, Wenaweser P, Cook S, Moschovitis A, Vogel R,
Kalesan B, Seiler C, Eberli F, Luscher TF, Meier B, Juni P, Windecker S. Five-year clinical and angiographic
outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the
Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial. Circulation
2011;123(24):2819-28, 6 p following 2828.
36.
Serruys PW, Ong AT, Piek JJ, Neumann FJ, van der Giessen WJ, Wiemer M, Zeiher A, Grube E,
Haase J, Thuesen L, Hamm C, Otto-Terlouw PC. A randomized comparison of a durable polymer Everolimuseluting stent with a bare metal coronary stent: The SPIRIT first trial. EuroIntervention 2005;1(1):58-65.
37.
Tsuchida K, Piek JJ, Neumann FJ, van der Giessen WJ, Wiemer M, Zeiher AM, Grube E, Haase J,
Thuesen L, Hamm CW, Veldhof S, Dorange C, Serruys PW. One-year results of a durable polymer everolimuseluting stent in de novo coronary narrowings (The SPIRIT FIRST Trial). EuroIntervention 2005;1(3):266-72.
38.
Beijk MA, Neumann FJ, Wiemer M, Grube E, Haase J, Thuesen L, Hamm C, Veldhof S, Dorange C,
Serruys PW, Piek JJ. Two-year results of a durable polymer everolimus-eluting stent in de novo coronary artery
stenosis (The SPIRIT FIRST Trial). EuroIntervention 2007;3(2):206-12.
39.
Wiemer M, Serruys PW, Miquel-Hebert K, Neumann FJ, Piek JJ, Grube E, Haase J, Thuesen L,
Hamm C. Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in
the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial. Catheter Cardiovasc
Interv 2010;75(7):997-1003.
40.
Grube E, Hauptmann KE, Buellesfeld L, Lim V, Abizaid A. Six-month results of a randomized study
to evaluate safety and efficacy of a Biolimus A9 eluting stent with a biodegradable polymer coating.
EuroIntervention 2005;1(1):53-7.
41.
Valgimigli M, Percoco G, Cicchitelli G, Ferrari F, Barbieri D, Ansani L, Guardigli G, Parrinello G,
Malagutti P, Soukhomovskaia O, Bettini A, Campo G, Ferrari R. High-dose bolus tirofiban and sirolimus eluting
stent versus abiciximab and bare metal stent in acute myocardial infarction (STRATEGY) study--protocol
design and demography of the first 100 patients. Cardiovasc Drugs Ther 2004;18(3):225-30.
42.
Valgimigli M, Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri D, Cicchitelli G, McFadden EP,
Merlini F, Ansani L, Guardigli G, Bettini A, Parrinello G, Boersma E, Ferrari R, Investigators S. Tirofiban and
sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial.
JAMA 2005;293(17):2109-17.
43.
Valgimigli M, Campo G, Arcozzi C, Malagutti P, Carletti R, Ferrari F, Barbieri D, Parrinello G,
Percoco G, Ferrari R. Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation
assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results
from the STRATEGY study. J Am Coll Cardiol 2007;50(2):138-45.
44.
Tebaldi M, Arcozzi C, Campo G, Percoco G, Ferrari R, Valgimigli M, Investigators S. The 5-year
clinical outcomes after a randomized comparison of sirolimus-eluting versus bare-metal stent implantation in
patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 2009;54(20):1900-1.
45.
Goy JJ, Stauffer JC, Siegenthaler M, Benoit A, Seydoux C. A prospective randomized comparison
between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial. J Am Coll
Cardiol 2005;45(2):308-11.
46.
Berger A, Stauffer JC, Seydoux C, Siegenthaler M, Benoit A, Goy JJ. Three-year follow-up of the first
prospective randomized comparison between paclitaxel and sirolimus stents: the TAXi-LATE trial. Catheter
Cardiovasc Interv 2007;70(2):163-6.
47.
Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, O'Shaughnessy CD, DeMaio S,
Hall P, Popma JJ, Koglin J, Russell ME, Investigators TV. Comparison of a polymer-based paclitaxel-eluting
stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial.
JAMA 2005;294(10):1215-23.
48.
Dawkins KD, Grube E, Guagliumi G, Banning AP, Zmudka K, Colombo A, Thuesen L, Hauptman K,
Marco J, Wijns W, Popma JJ, Koglin J, Russell ME, Investigators TV. Clinical efficacy of polymer-based
paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter,
randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation
2005;112(21):3306-13.
49.
Grube E, Dawkins KD, Guagliumi G, Banning AP, Zmudka K, Colombo A, Thuesen L, Hauptman K,
Marco J, Wijns W, Popma JJ, Buellesfeld L, Koglin J, Russell ME. TAXUS VI 2-year follow-up: randomized
comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions.
Eur Heart J 2007;28(21):2578-82.
50.
Dawkins KD. Long-Term Outcomes in Complex Patients Treated with the TAXUS Moderated Release
Stent: TAXUS IV Three Year Clinical Results.
51.
Grube E, Dawkins KD, Guagliumi G, Banning AP, Zmudka K, Thuesen L, Hauptmann KE, Marco J,
Wijns W, Koglin J. Long-Term Outcomes in Complex Patients Treated with the TAXUS Moderated Release Stent:
TAXUS IV 4-Year. http://www.crtonline.org/flash.aspx?PAGE_ID=4464.
52.
Grube E, Dawkins KD, Guagliumi G, Banning A, Zmudka K, Colombo A, Thuesen L, Hauptman K,
Marco J, Wijns W, Joshi A, Mascioli S. TAXUS VI final 5-year results: a multicentre, randomised trial
comparing polymer-based moderate-release paclitaxel-eluting stent with a bare metal stent for treatment of long,
complex coronary artery lesions. EuroIntervention 2009;4(5).
53.
Červinka P, Costa MA, Angiolillo DJ, Špaček R, Bystroň M, Kvašňák M, Veselka J, Nanda H,
Futamatsu H, Futamatsu K. “Head-to-head comparison between sirolimus-eluting and paclitaxel-eluting stents
in patients with complex coronary artery disease: An intravascular ultrasound study”. Catheterization and
Cardiovascular Interventions 2006;67(6):846-851.
54.
Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T, Popma JJ, Fitzgerald PJ, Bonan R,
Kuntz RE, Investigators EI. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting
phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic
results of the ENDEAVOR II trial. Circulation 2006;114(8):798-806.
55.
Meredith I. ENDEAVOR Clinical Program Update.
http://www.crtonline.org/flash.aspx?PAGE_ID=1953.
56.
Zeiher A. ENDEAVOR I & II Update. http://www.crtonline.org/flash.aspx?PAGE_ID=4454.
57.
Fajadet J. ENDEAVOR Clinical Program Update.
http://www.crtonline.org/flash.aspx?PAGE_ID=5360.
58.
Fajadet J, Wijns W, Laarman G-J, Kuck K-H, Ormiston JA, Baldus S, Hauptmann K-E, Suttorp M,
Drzewiecki J, Pieper M, Schultheiss H-P, Mauri L. Long-term follow-up of the randomised controlled trial to
evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary
artery lesions: five year outcomes in the ENDEAVOR II study. EuroIntervention 2010;6(5):562-567.
59.
Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O'Shaughnessy C, Ball MW, Turco M, Applegate
RJ, Gurbel PA, Midei MG, Badre SS, Mauri L, Thompson KP, LeNarz LA, Kuntz RE, Investigators EI.
Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a
randomized controlled trial. J Am Coll Cardiol 2006;48(12):2440-7.
60.
Eisenstein EL, Leon MB, Kandzari DE, Mauri L, Edwards R, Kong DF, Cowper PA, Anstrom KJ,
Investigators EI. Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the
cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of
the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting
Coronary Stent System in De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv
2009;2(12):1199-207.
61.
Kandzari DE, Mauri L, Popma JJ, Turco MA, Gurbel PA, Fitzgerald PJ, Leon MB. Late-term clinical
outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A
Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System
Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
JACC Cardiovasc Interv 2011;4(5):543-50.
62.
Tierala I, Syvänne M, Kupari M. Comparison of Paclitaxel-Eluting with Bare Metal Stents in Acute
Myocardial Infarction: The HAAMU-STENT-study. http://www.tctmd.com/show.aspx?id=56036.
63.
Kalesan B, Pilgrim T, Heinimann K, Raber L, Stefanini GG, Valgimigli M, da Costa BR, Mach F,
Luscher TF, Meier B, Windecker S, Juni P. Comparison of drug-eluting stents with bare metal stents in patients
with ST-segment elevation myocardial infarction. Eur Heart J 2012;33(8):977-87.
64.
Mehilli J, Dibra A, Kastrati A, Pache J, Dirschinger J, Schomig A, Intracoronary Drug-Eluting
Stenting to Abrogate Restenosis in Small Arteries Study I. Randomized trial of paclitaxel- and sirolimus-eluting
stents in small coronary vessels. Eur Heart J 2006;27(3):260-6.
65.
Kim YH, Park SW, Lee SW, Park DW, Yun SC, Lee CW, Hong MK, Kim HS, Ko JK, Park JH, Lee JH,
Choi SW, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Park SJ, Long DESIISI. Sirolimus-eluting stent
versus paclitaxel-eluting stent for patients with long coronary artery disease. Circulation 2006;114(20):2148-53.
66.
Pasceri V, Granatelli A, Pristipino C, Pelliccia F, Speciale G, Pironi B, Roncell A, Richichi G. A
Randomized Trial of a Rapamycin-Eluting Stent in Acute Myocardial Infarction: Preliminary Results. The
American Journal of Cardiology 2003;92(6, Supplement 1):1-4.
67.
Luca G, Valgimigli M, Spaulding C, Menichelli M, Rocca H-L, Hoeven B, Lorenzo E, Llera L-SD,
Pasceri V, Pittl U, Percoco G, Violini R, Stone G. Short and long-term benefits of sirolimus-eluting stent in STsegment elevation myocardial infarction: a meta-analysis of randomized trials. Journal of Thrombosis and
Thrombolysis 2009;28(2):200-210.
68.
Laarman GJ, Suttorp MJ, Dirksen MT, van Heerebeek L, Kiemeneij F, Slagboom T, van der Wieken
LR, Tijssen JG, Rensing BJ, Patterson M. Paclitaxel-eluting versus uncoated stents in primary percutaneous
coronary intervention. N Engl J Med 2006;355(11):1105-13.
69.
Dirksen MT, Vink MA, Suttorp MJ, Tijssen JG, Patterson MS, Slagboom T, Kiemeneij F, Laarman GJ,
Paclitaxel-Eluting Stent versus Conventional S, in Myocardial Infarction with STSEi. Two year follow-up after
primary PCI with a paclitaxel-eluting stent versus a bare-metal stent for acute ST-elevation myocardial
infarction (the PASSION trial): a follow-up study. EuroIntervention 2008;4(1):64-70.
70.
Vink MA, Dirksen MT, Suttorp MJ, Tijssen JG, van Etten J, Patterson MS, Slagboom T, Kiemeneij F,
Laarman GJ. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent
versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the
PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation)
trial. JACC Cardiovasc Interv 2011;4(1):24-9.
71.
Rahel BM, Laarman GJ, Suttorp MJ, investigators PIs. Primary stenting of occluded native coronary
arteries II--rationale and design of the PRISON II study: a randomized comparison of bare metal stent
implantation with sirolimus-eluting stent implantation for the treatment of chronic total coronary occlusions. Am
Heart J 2005;149(3):e1-3.
72.
Suttorp MJ, Laarman GJ, Rahel BM, Kelder JC, Bosschaert MA, Kiemeneij F, Ten Berg JM, Bal ET,
Rensing BJ, Eefting FD, Mast EG. Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON
II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the
treatment of total coronary occlusions. Circulation 2006;114(9):921-8.
73.
Rahel BM, Laarman GJ, Kelder JC, Ten Berg JM, Suttorp MJ. Three-year clinical outcome after
primary stenting of totally occluded native coronary arteries: a randomized comparison of bare-metal stent
implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (Primary
Stenting of Totally Occluded Native Coronary Arteries [PRISON] II study). Am Heart J 2009;157(1):149-55.
74.
Van den Branden BJ, Rahel BM, Laarman GJ, Slagboom T, Kelder JC, Ten Berg JM, Suttorp MJ.
Five-year clinical outcome after primary stenting of totally occluded native coronary arteries: a randomised
comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total
coronary occlusions (PRISON II study). EuroIntervention 2012;7(10):1189-96.
75.
Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, Sousa E, Stoll HP,
Investigators RT. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial:
a randomized controlled trial. JAMA 2006;295(8):895-904.
76.
Morice MC, Serruys PW, Colombo A, Meier B, Tamburino C, Guagliumi G, Sousa E, Mendiz O,
Grube E. Prospective Randomized Multicenter Head-to-Head Comparison of the Sirolimus-Eluting Stent and
the Paclitaxel-Eluting Stent: 2-Year Outcome of the REALITY Trial.
http://www.crtonline.org/flash.aspx?PAGE_ID=3389.
77.
Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Bruining N, Van den Branden F,
Van Langenhove G. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent
implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical
follow-up of the RRISC Trial. J Am Coll Cardiol 2006;48(12):2423-31.
78.
Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Van den Branden F, Van
Langenhove G, Investigators DR. Increased late mortality after sirolimus-eluting stents versus bare-metal stents
in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial. J Am Coll Cardiol
2007;50(3):261-7.
79.
Kelbaek H, Thuesen L, Helqvist S, Clemmensen P, Klovgaard L, Kaltoft A, Andersen B, Thuesen H,
Engstrom T, Botker HE, Saunamaki K, Krusell LR, Jorgensen E, Hansen HH, Christiansen EH, Ravkilde J,
Kober L, Kofoed KF, Terkelsen CJ, Lassen JF, Investigators D. Drug-eluting versus bare metal stents in patients
with st-segment-elevation myocardial infarction: eight-month follow-up in the Drug Elution and Distal
Protection in Acute Myocardial Infarction (DEDICATION) trial. Circulation 2008;118(11):1155-62.
80.
Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrie D, Slama MS, Merkely B, Erglis A,
Margheri M, Varenne O, Cebrian A, Stoll HP, Snead DB, Bode C, Investigators T. Sirolimus-eluting versus
uncoated stents in acute myocardial infarction. N Engl J Med 2006;355(11):1093-104.
81.
Spaulding C, Teiger E, Commeau P, Varenne O, Bramucci E, Slama M, Beatt K, Tirouvanziam A,
Polonski L, Stella PR, Clugston R, Fajadet J, de Boisgelin X, Bode C, Carrie D, Erglis A, Merkely B, Hosten S,
Cebrian A, Wang P, Stoll HP, Henry P. Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer
sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty). JACC
Cardiovasc Interv 2011;4(1):14-23.
82.
Diaz de la Llera LS, Ballesteros S, Nevado J, Fernandez M, Villa M, Sanchez A, Retegui G, Garcia D,
Martinez A. Sirolimus-eluting stents compared with standard stents in the treatment of patients with primary
angioplasty. Am Heart J 2007;154(1):164 e1-6.
83.
Chan C, Zambahari R, Kaul U, Lau CP, Whitworth H, Cohen S, Buchbinder M, Investigators D. A
randomized comparison of sirolimus-eluting versus bare metal stents in the treatment of diabetic patients with
native coronary artery lesions: the DECODE study. Catheter Cardiovasc Interv 2008;72(5):591-600.
84.
Erglis A, Narbute I, Kumsars I, Jegere S, Mintale I, Zakke I, Strazdins U, Saltups A. A randomized
comparison of paclitaxel-eluting stents versus bare-metal stents for treatment of unprotected left main coronary
artery stenosis. J Am Coll Cardiol 2007;50(6):491-7.
85.
Narbute I, Jegere S, Kumsars I, Mintale I, Zakke I, Bumeistere K, Sondore D, Grave A, Erglis A. Are
paclitaxel-eluting stents better in unprotected left main coronary artery disease? Three-year clinical and
intravascular imaging results from a randomized study. Medicina (Kaunas) 2011;47(10):536-43.
86.
Chevalier B, Serruys PW, Silber S, Garcia E, Suryapranata H, Hauptmann K, Wijns W, Schuler G,
Fath-Ordoubadi F, Worthley S, Thuesen L, Meredith I, Bressers M, Nagai H, Paunovic D. Randomised
comparison of Nobori, biolimus A9-eluting coronary stent with a Taxus(R), paclitaxel-eluting coronary stent in
patients with stenosis in native coronary arteries: the Nobori 1 trial. EuroIntervention 2007;2(4):426-34.
87.
Silber S. No Late and no Very Late Stent Thrombosis with a Drug-Eluting Stent of the Second
Generation: 2 Years Results from the Randomized NOBORI-I trial.
http://www.crtonline.org/flash.aspx?PAGE_ID=5903.
88.
Ortolani P, Marzocchi A, Marrozzini C, Palmerini T, Saia F, Taglieri N, Aquilina M, Baldazzi F,
Silenzi S, Cooke RM, Reggiani ML, Branzi A. Randomized comparative trial of a thin-strut bare metal cobaltchromium stent versus a sirolimus-eluting stent for coronary revascularization. Catheter Cardiovasc Interv
2007;69(6):790-8.
89.
Pan M, Suarez de Lezo J, Medina A, Romero M, Delgado A, Segura J, Ojeda S, Mazuelos F,
Hernandez E, Melian F, Pavlovic D, Esteban F, Herrador J. Drug-eluting stents for the treatment of bifurcation
lesions: A randomized comparison between paclitaxel and sirolimus stents. American Heart Journal
2007;153(1):15.e1-15.e7.
90.
Petronio AS, De Carlo M, Branchitta G, Papini B, Ciabatti N, Gistri R, Cortese B, Gherarducci G,
Barsotti A. Randomized comparison of sirolimus and paclitaxel drug-eluting stents for long lesions in the left
anterior descending artery: an intravascular ultrasound study. J Am Coll Cardiol 2007;49(5):539-46.
91.
Baumgart D, Klauss V, Baer F, Hartmann F, Drexler H, Motz W, Klues H, Hofmann S, Volker W,
Pfannebecker T, Stoll HP, Nickenig G, Investigators SS. One-year results of the SCORPIUS study: a German
multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. J Am Coll Cardiol
2007;50(17):1627-34.
92.
Sinning JM, Baumgart D, Werner N, Klauss V, Baer FM, Hartmann F, Drexler H, Motz W, Klues H,
Voelker W, Pfannebecker T, Stoll HP, Nickenig G, Study S. Five-year results of the Multicenter Randomized
Controlled Open-Label Study of the CYPHER Sirolimus-Eluting Stent in the Treatment of Diabetic Patients
with De Novo Native Coronary Artery Lesions (SCORPIUS) study: a German multicenter investigation on the
effectiveness of sirolimus-eluting stents in diabetic patients. Am Heart J 2012;163(3):446-53, 453 e1.
93.
Chechi T, Vittori G, Biondi Zoccai GG, Vecchio S, Falchetti E, Spaziani G, Baldereschi G, Giglioli C,
Valente S, Margheri M. Single-center randomized evaluation of paclitaxel-eluting versus conventional stent in
acute myocardial infarction (SELECTION). J Interv Cardiol 2007;20(4):282-91.
94.
Menichelli M, Parma A, Pucci E, Fiorilli R, De Felice F, Nazzaro M, Giulivi A, Alborino D, Azzellino
A, Violini R. Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial
Infarction (SESAMI). J Am Coll Cardiol 2007;49(19):1924-30.
95.
Violini R, Musto C, De Felice F, Nazzaro MS, Cifarelli A, Petitti T, Fiorilli R. Maintenance of longterm clinical benefit with sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction 3year results of the SESAMI (sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction) trial.
J Am Coll Cardiol 2010;55(8):810-4.
96.
Musto C, Fiorilli R, De Felice F, Patti G, Nazzaro MS, Scappaticci M, Bernardi L, Violini R. Longterm outcome of sirolimus-eluting vs bare-metal stent in the setting of acute myocardial infarction: 5-year
results of the SESAMI trial. Int J Cardiol 2011.
97.
Strozzi M, Ani D. (2007) Comparison of stent graft, sirolimus stent, and bare metal stent implanted in
patients with acute coronary syndrome: clinical and angiographic follow-up. Croatian Medical Journal.
98.
Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Hong MK, Rhee KS, Chae JK, Ko JK, Park
JH, Lee JH, Choi SW, Jeong JO, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Kim HS, Park SJ. A
randomized comparison of sirolimus- versus Paclitaxel-eluting stent implantation in patients with diabetes
mellitus. J Am Coll Cardiol 2008;52(9):727-33.
99.
Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Hong MK, Rhee KS, Chae JK, Ko JK, Park
JH, Lee JH, Choi SW, Jeong JO, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Kim HS, Park SJ. A
randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes
mellitus 2-year clinical outcomes of the DES-DIABETES trial. J Am Coll Cardiol 2009;53(9):812-3.
100.
Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Kang SJ, Rhee KS, Chae JK, Ko JK, Park
JH, Lee JH, Choi SW, Jeong JO, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Kim HS, Park SJ. A
randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes
mellitus: 4-year clinical outcomes of DES-DIABETES (drug-eluting stent in patients with DIABETES mellitus)
trial. JACC Cardiovasc Interv 2011;4(3):310-6.
101.
Maresta A, Varani E, Balducelli M, Varbella F, Lettieri C, Uguccioni L, Sangiorgio P, Zoccai GB.
Comparison of Effectiveness and Safety of Sirolimus-Eluting Stents Versus Bare-Metal Stents in Patients With
Diabetes Mellitus (from the Italian Multicenter Randomized DESSERT Study). The American Journal of
Cardiology 2008;101(11):1560-1566.
102.
Kim MH, Hong SJ, Cha KS, Park HS, Chae SC, Hur SH, Gwon HC, Bae JH, Lim DS. Effect of
Paclitaxel-eluting versus sirolimus-eluting stents on coronary restenosis in Korean diabetic patients. J Interv
Cardiol 2008;21(3):225-31.
103.
Hong SJ, Kim MH, Cha KS, Park HS, Chae SC, Hur SH, Gwon HC, Bae JH, Lim DS. Comparison of
three-year clinical outcomes between sirolimus-versus paclitaxel-eluting stents in diabetic patients: prospective
randomized multicenter trial. Catheter Cardiovasc Interv 2010;76(7):924-33.
104.
Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V,
Eberli F, Corti R, Wijns W, Morice MC, di Mario C, Davies S, van Geuns RJ, Eerdmans P, van Es GA, Meier B,
Juni P. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer
for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 2008;372(9644):1163-73.
105.
Garg S, Wykrzykowska J, Serruys PW, de Vries T, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger
T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, Tyczynski P, van Geuns RJ, Eerdmans P, van
Es GA, Meier B, Juni P, Windecker S. The outcome of bifurcation lesion stenting using a biolimus-eluting stent
with a bio-degradable polymer compared to a sirolimus-eluting stent with a durable polymer. EuroIntervention
2011;6(8):928-35.
106.
Klauss V, Serruys PW, Pilgrim T, Buszman P, Linke A, Ischinger T, Eberli F, Corti R, Wijns W, Morice
MC, di Mario C, van Geuns RJ, van Es GA, Kalesan B, Wenaweser P, Juni P, Windecker S. 2-year clinical
follow-up from the randomized comparison of biolimus-eluting stents with biodegradable polymer and
sirolimus-eluting stents with durable polymer in routine clinical practice. JACC Cardiovasc Interv
2011;4(8):887-95.
107.
Wykrzykowska J, Serruys P, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W,
Morice MC, Di Mario C, Van Geuns RJ, Van Es GA, Juni P, Windecker S. The three year follow-up of the
randomised "all-comers" trial of a biodegradable polymer biolimus-eluting stent versus permanent polymer
sirolimus-eluting stent (LEADERS). EuroIntervention 2011;7(7):789-95.
108.
Stefanini GG, Kalesan B, Serruys PW, Heg D, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F,
Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, van Es GA, Meier B, Windecker S,
Juni P. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer
sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised
non-inferiority trial. Lancet 2011;378(9807):1940-8.
109.
Serruys P. LEADERS 5-Year: A Prospective, Randomized Trial of Bioabsorbable Polymer-based
Biolimus-Eluting vs. Sirolimus-Eluting Stents. http://www.tctmd.com/show.aspx?id=114397.
110.
Li JJ, Qin XW, Yang XC, Li ZC, Zeng HS, Xu B, Gao Z, Wu YJ, Zhang X, Zhang CY. Randomized
comparison of early inflammatory response after sirolimus-eluting stent vs bare metal stent implantation in
native coronary lesions. Clin Chim Acta 2008;396(1-2):38-42.
111.
van der Hoeven BL, Liem SS, Jukema JW, Suraphakdee N, Putter H, Dijkstra J, Atsma DE, Bootsma
M, Zeppenfeld K, Oemrawsingh PV, van der Wall EE, Schalij MJ. Sirolimus-eluting stents versus bare-metal
stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular
ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study. J Am Coll
Cardiol 2008;51(6):618-26.
112.
Atary JZ, van der Hoeven BL, Liem SS, Jukema JW, van der Bom JG, Atsma DE, Bootsma M,
Zeppenfeld K, van der Wall EE, Schalij MJ. Three-year outcome of sirolimus-eluting versus bare-metal stents
for the treatment of ST-segment elevation myocardial infarction (from the MISSION! Intervention Study). Am J
Cardiol 2010;106(1):4-12.
113.
Boden H, van der Hoeven BL, Liem SS, Atary JZ, Cannegieter SC, Atsma DE, Bootsma M, Jukema
JW, Zeppenfeld K, Oemrawsingh PV, van der Wall EE, Schalij MJ. Five-year clinical follow-up from the
MISSION! Intervention Study: sirolimus-eluting stent versus bare metal stent implantation in patients with STsegment elevation myocardial infarction, a randomised controlled trial. EuroIntervention 2012;7(9):1021-9.
114.
Valgimigli M, Campo G, Percoco G, Bolognese L, Vassanelli C, Colangelo S, de Cesare N, Rodriguez
AE, Ferrario M, Moreno R, Piva T, Sheiban I, Pasquetto G, Prati F, Nazzaro MS, Parrinello G, Ferrari R,
Multicentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab With Sirolimus-Eluting Stent or
Bare Metal Stent in Acute Myocardial Infarction Study I. Comparison of angioplasty with infusion of tirofiban
or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the
MULTISTRATEGY randomized trial. JAMA 2008;299(15):1788-99.
115.
Valgimigli M, Campo G, Gambetti S, Bolognese L, Ribichini F, Colangelo S, de Cesare N, Rodriguez
AE, Russo F, Moreno R, Piva T, Sheiban I, Penzo C, Prati F, Nazzaro MS, Diaz Fernandez JF, Vassanelli C,
Parrinello G, Ferrari R, For the MeoSh-dbTvAwsesoBMSiAMIsi. Three-year follow-up of the MULTIcentre
evaluation of Single high-dose Bolus TiRofiban versus Abciximab with Sirolimus-eluting STEnt or Bare-Metal
Stent in Acute Myocardial Infarction StudY (MULTISTRATEGY). Int J Cardiol 2011.
116.
Valgimigli M, Bolognese L, Anselmi M, Campo G, Rodriguez AE, de Cesare N, Cohen DJ, Sheiban I,
Colangelo S, Pasquetto G, Hamon M, Vranckx P, Ferrario M, Prati F, Agostoni P, Malagutti P, Arcozzi C,
Parrinello G, Vassanelli C, Ferrari R, Percoco G. Two-by-two factorial comparison of high-bolus-dose tirofiban
followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in
patients with acute myocardial infarction: design and rationale for the MULTI-STRATEGY trial. Am Heart J
2007;154(1):39-45.
117.
Lee JH, Kim HS, Lee SW, Park JH, Choi SW, Jeong JO, Cho Y, Lee N, Rhee KS, Ko JK, Seong IW.
Prospective randomized comparison of sirolimus- versus paclitaxel-eluting stents for the treatment of acute STelevation myocardial infarction: pROSIT trial. Catheter Cardiovasc Interv 2008;72(1):25-32.
118.
Kim HS, Lee JH, Lee SW, Kim YH, Park JH, Choi SW, Jeong JO, Seong IW, Rhee KS, Ko JK, Jo SH,
Choi YJ. Long-term safety and efficacy of sirolimus- vs. paclitaxel-eluting stent implantation for acute STelevation myocardial infarction: 3-year follow-up of the PROSIT trial. Int J Cardiol 2011;147(2):253-7.
119.
Galloe AM, Thuesen L, Kelbaek H, Thayssen P, Rasmussen K, Hansen PR, Bligaard N, Saunamaki K,
Junker A, Aaroe J, Abildgaard U, Ravkilde J, Engstrom T, Jensen JS, Andersen HR, Botker HE, Galatius S,
Kristensen SD, Madsen JK, Krusell LR, Abildstrom SZ, Stephansen GB, Lassen JF, Investigators SOI.
Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II
randomized trial. JAMA 2008;299(4):409-16.
120.
Caixeta A, Lansky AJ, Serruys PW, Hermiller JB, Ruygrok P, Onuma Y, Gordon P, Yaqub M, MiquelHebert K, Veldhof S, Sood P, Su X, Jonnavithula L, Sudhir K, Stone GW, Spirit, II, Investigators III. Clinical
follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A
Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients
With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational
Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De
Novo Native Coronary Artery Lesions) randomized trials. JACC Cardiovasc Interv 2010;3(12):1220-8.
121.
Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip
DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ, Investigators SI. Comparison of an everolimus-eluting stent and a
paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 2008;299(16):190313.
122.
Nikolsky E, Lansky AJ, Sudhir K, Doostzadeh J, Cutlip DE, Piana R, Su X, White R, Simonton CA,
Stone GW. SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and
paclitaxel-eluting stents in patients with coronary artery disease. Am Heart J 2009;158(4):520-526 e2.
123.
Applegate RJ, Yaqub M, Hermiller JB, Sood P, Yu S, Doostzadeh J, Williams JE, Farhat N, Caputo R,
Lansky AJ, Cutlip DE, Sudhir K, Stone GW. Long-term (three-year) safety and efficacy of everolimus-eluting
stents compared to paclitaxel-eluting stents (from the SPIRIT III Trial). Am J Cardiol 2011;107(6):833-40.
124.
Mehran R, Brodie B, Cox DA, Grines CL, Rutherford B, Bhatt DL, Dangas G, Feit F, Ohman EM,
Parise H, Fahy M, Lansky AJ, Stone GW. The Harmonizing Outcomes with RevasculariZatiON and Stents in
Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale. Am Heart J 2008;156(1):4456.
125.
Stone GW, Lansky AJ, Pocock SJ, Gersh BJ, Dangas G, Wong SC, Witzenbichler B, Guagliumi G,
Peruga JZ, Brodie BR, Dudek D, Mockel M, Ochala A, Kellock A, Parise H, Mehran R, Investigators H-AT.
Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med
2009;360(19):1946-59.
126.
Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann
F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Fahy M, Parise H, Mehran R, Investigators H-AT. Heparin plus a
glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal
stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised
controlled trial. Lancet 2011;377(9784):2193-204.
127.
Mehilli J, Kastrati A, Byrne RA, Bruskina O, Iijima R, Schulz S, Pache J, Seyfarth M, Massberg S,
Laugwitz KL, Dirschinger J, Schomig A, Stenting L-MI, Angiographic Results: Drug-Eluting Stents for
Unprotected Coronary Left Main Lesions Study I. Paclitaxel- versus sirolimus-eluting stents for unprotected left
main coronary artery disease. J Am Coll Cardiol 2009;53(19):1760-8.
128.
Byrne RA, Mehilli J, Iijima R, Schulz S, Pache J, Seyfarth M, Schomig A, Kastrati A. A polymer-free
dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drugeluting stents. Eur Heart J 2009;30(8):923-31.
129.
Byrne RA, Kastrati A, Tiroch K, Schulz S, Pache J, Pinieck S, Massberg S, Seyfarth M, Laugwitz KL,
Birkmeier KA, Schomig A, Mehilli J, Investigators I-T-. 2-year clinical and angiographic outcomes from a
randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected]
drug-eluting stents. J Am Coll Cardiol 2010;55(23):2536-43.
130.
Byrne RA, Kastrati A, Kufner S, Massberg S, Birkmeier KA, Laugwitz K-L, Schulz S, Pache J,
Fusaro M, Seyfarth M, Schömig A, Mehilli J. Randomized, non-inferiority trial of three limus agent-eluting
stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3
Limus-Eluting Stents (ISAR-TEST-4) Trial. European Heart Journal 2009;30(20):2441-2449.
131.
Byrne RA, Kastrati A, Massberg S, Wieczorek A, Laugwitz KL, Hadamitzky M, Schulz S, Pache J,
Fusaro M, Hausleiter J, Schomig A, Mehilli J, Investigators I-T. Biodegradable polymer versus permanent
polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery
disease: 3-year outcomes from a randomized clinical trial. J Am Coll Cardiol 2011;58(13):1325-31.
132.
Juwana YB, Suryapranata H, Ottervanger JP, De Luca G, van't Hof AW, Dambrink JH, de Boer MJ,
Gosselink AT, Hoorntje JC. Comparison of rapamycin- and paclitaxel-eluting stents in patients undergoing
primary percutaneous coronary intervention for ST-elevation myocardial infarction. Am J Cardiol
2009;104(2):205-9.
133.
Li JJ, Yan HB, Xiang XP, Qin XW, Zhang CY. Comparison of changes in early inflammatory markers
between sirolimus- and paclitaxel-eluting stent implantation. Cardiovasc Drugs Ther 2009;23(2):137-43.
134.
Chevalier B, Silber S, Park SJ, Garcia E, Schuler G, Suryapranata H, Koolen J, Hauptmann KE, Wijns
W, Morice MC, Carrie D, van Es GA, Nagai H, Detiege D, Paunovic D, Serruys PW, Investigators NC.
Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberte paclitaxeleluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2. Circ
Cardiovasc Interv 2009;2(3):188-95.
135.
Di Lorenzo E, De Luca G, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Mariello C,
Siano F, Pagliuca MR, Stanco G, Rosato G. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare
Metal Stent in Primary Angioplasty) Randomized Trial. JACC: Cardiovascular Interventions 2009;2(6):515-523.
136.
Di Lorenzo E, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F,
Pagliuca MR, Stanco G, Rosato G, De Luca G. Benefits of drug-eluting stents as compared to bare metal stent in
ST-segment elevation myocardial infarction: Four year results of the PaclitAxel or Sirolimus-Eluting stent vs
bare metal stent in primary angiOplasty (PASEO) randomized trial. American Heart Journal 2009;158(4):e43e50.
137.
Brilakis ES, Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Haagen D, Saeed B, Gadiparthi C,
Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S. A
randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft
lesions the SOS (Stenting of Saphenous Vein Grafts) trial. J Am Coll Cardiol 2009;53(11):919-28.
138.
Brilakis ES, Lichtenwalter C, Abdel-karim AR, de Lemos JA, Obel O, Addo T, Roesle M, Haagen D,
Rangan BV, Saeed B, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P,
Banerjee S. Continued benefit from paclitaxel-eluting compared with bare-metal stent implantation in saphenous
vein graft lesions during long-term follow-up of the SOS (Stenting of Saphenous Vein Grafts) trial. JACC
Cardiovasc Interv 2011;4(2):176-82.
139.
Claessen BE, Beijk MA, Legrand V, Ruzyllo W, Manari A, Varenne O, Suttorp MJ, Tijssen JG,
Miquel-Hebert K, Veldhof S, Henriques JP, Serruys PW, Piek JJ. Two-year clinical, angiographic, and
intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with
de novo native coronary artery lesions: the SPIRIT II trial. Circ Cardiovasc Interv 2009;2(4):339-47.
140.
Garg S, Serruys P, Onuma Y, Dorange C, Veldhof S, Miquel-Hebert K, Sudhir K, Boland J, Huber K,
Garcia E, te Riele JA, Investigators SI. 3-year clinical follow-up of the XIENCE V everolimus-eluting coronary
stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical
Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de
novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 2009;2(12):1190-8.
141.
Garg S, Serruys PW, Miquel-Hebert K, Investigators SI. Four-year clinical follow-up of the XIENCE
V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the
SPIRIT II trial. Catheter Cardiovasc Interv 2011;77(7):1012-7.
142.
Onuma Y, Miquel-Hebert K, Serruys PW, Investigators SI. Five-year long-term clinical follow-up of
the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary
artery disease: the SPIRIT II trial. EuroIntervention 2013;8(9):1047-51.
143.
Lee CW, Park DW, Lee SH, Kim YH, Hong MK, Kim JJ, Park SW, Yun SC, Seong IW, Lee JH, Lee
NH, Cho YH, Cheong SS, Lim DS, Yang JY, Lee SG, Kim KS, Yoon J, Jeong MH, Seung KB, Hong TJ, Park SJ,
Investigators Z-A. Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting
stents in patients with ST-elevation myocardial infarction. Am J Cardiol 2009;104(10):1370-6.
144.
Pfisterer M, Bertel O, Bonetti PO, Brunner-La Rocca HP, Eberli FR, Erne P, Galatius S, Hornig B,
Kiowski W, Pachinger O, Pedrazzini G, Rickli H, De Servi S, Kaiser C. Drug-eluting or bare-metal stents for
large coronary vessel stenting? The BASKET-PROVE (PROspective Validation Examination) trial: Study
protocol and design. American Heart Journal 2008;155(4):609-614.
145.
Kaiser C, Galatius S, Erne P, Eberli F, Alber H, Rickli H, Pedrazzini G, Hornig B, Bertel O, Bonetti P,
De Servi S, Brunner-La Rocca HP, Ricard I, Pfisterer M, Group B-PS. Drug-eluting versus bare-metal stents in
large coronary arteries. N Engl J Med 2010;363(24):2310-9.
146.
Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, Smits PC. Secondgeneration everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial.
Lancet 2010;375(9710):201-9.
147.
Smits PC, Kedhi E, Royaards KJ, Joesoef KS, Wassing J, Rademaker-Havinga TA, McFadden E. 2year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary
revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the
paclitaxel eluting TAXUS LIBERTE stent in all-comers: a randomized open label trial). J Am Coll Cardiol
2011;58(1):11-8.
148.
Leon MB, Mauri L, Popma JJ, Cutlip DE, Nikolsky E, O'Shaughnessy C, Overlie PA, McLaurin BT,
Solomon SL, Douglas JS, Jr., Ball MW, Caputo RP, Jain A, Tolleson TR, Reen BM, 3rd, Kirtane AJ, Fitzgerald
PJ, Thompson K, Kandzari DE, Investigators EI. A randomized comparison of the ENDEAVOR zotarolimuseluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes
from the ENDEAVOR IV trial. J Am Coll Cardiol 2010;55(6):543-54.
149.
Leon MB, Kandzari DE, Eisenstein EL, Anstrom KJ, Mauri L, Cutlip DE, Nikolsky E, O'Shaughnessy
C, Overlie PA, Kirtane AJ, McLaurin BT, Solomon SL, Douglas Jr JS, Popma JJ. Late Safety, Efficacy, and
Cost-Effectiveness of a Zotarolimus-Eluting Stent Compared With a Paclitaxel-Eluting Stent in Patients With
De Novo Coronary Lesions: 2-Year Follow-Up From the ENDEAVOR IV Trial (Randomized, Controlled Trial
of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting
Coronary Stent System in De Novo Native Coronary Artery Lesions). JACC: Cardiovascular Interventions
2009;2(12):1208-1218.
150.
Leon MB, Nikolsky E, Cutlip DE, Mauri L, Liberman H, Wilson H, Patterson J, Moses J, Kandzari
DE. Improved Late Clinical Safety With Zotarolimus-Eluting Stents Compared With Paclitaxel-Eluting Stents in
Patients With De Novo Coronary Lesions: 3-Year Follow-Up From the ENDEAVOR IV (Randomized
Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) Trial.
JACC: Cardiovascular Interventions 2010;3(10):1043-1050.
151.
Rubartelli P, Petronio AS, Guiducci V, Sganzerla P, Bolognese L, Galli M, Sheiban I, Chirillo F,
Ramondo A, Bellotti S, Gruppo Italiano di Studio sullo Stent nelle Occlusioni Coronariche IIGI. Comparison of
sirolimus-eluting and bare metal stent for treatment of patients with total coronary occlusions: results of the
GISSOC II-GISE multicentre randomized trial. Eur Heart J 2010;31(16):2014-20.
152.
Sanchez PL, Gimeno F, Ancillo P, Sanz JJ, Alonso-Briales JH, Bosa F, Santos I, Sanchis J,
Bethencourt A, Lopez-Messa J, de Prado AP, Alonso JJ, San Roman JA, Fernandez-Aviles F. Role of the
paclitaxel-eluting stent and tirofiban in patients with ST-elevation myocardial infarction undergoing
postfibrinolysis angioplasty: the GRACIA-3 randomized clinical trial. Circ Cardiovasc Interv 2010;3(4):297307.
153.
Mehilli J, Byrne RA, Tiroch K, Pinieck S, Schulz S, Kufner S, Massberg S, Laugwitz KL, Schomig A,
Kastrati A, Investigators I-D. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of
coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic
Results: Drug Eluting Stents for In-Stent Restenosis 2) study. J Am Coll Cardiol 2010;55(24):2710-6.
154.
Guagliumi G, Sirbu V, Bezerra H, Biondi-Zoccai G, Fiocca L, Musumeci G, Matiashvili A,
Lortkipanidze N, Tahara S, Valsecchi O, Costa M. Strut coverage and vessel wall response to zotarolimuseluting and bare-metal stents implanted in patients with ST-segment elevation myocardial infarction: the
OCTAMI (Optical Coherence Tomography in Acute Myocardial Infarction) Study. JACC Cardiovasc Interv
2010;3(6):680-7.
155.
Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ,
Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, DiMario C, Manoharan G, Kornowski R, Ischinger
T, Bartorelli A, Ronden J, Bressers M, Gobbens P, Negoita M, van Leeuwen F, Windecker S. Comparison of
zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010;363(2):136-46.
156.
Silber S, Windecker S, Vranckx P, Serruys PW, investigators RAC. Unrestricted randomised use of
two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the
RESOLUTE All Comers trial. Lancet 2011;377(9773):1241-7.
157.
Rasmussen K, Maeng M, Kaltoft A, Thayssen P, Kelbaek H, Tilsted HH, Abildgaard U, Christiansen
EH, Engstrom T, Krusell LR, Ravkilde J, Hansen PR, Hansen KN, Abildstrom SZ, Aaroe J, Jensen JS,
Kristensen SD, Botker HE, Madsen M, Johnsen SP, Jensen LO, Sorensen HT, Thuesen L, Lassen JF, group SOIs.
Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT
OUT III): a randomised controlled superiority trial. Lancet 2010;375(9720):1090-9.
158.
Maeng M, Tilsted HH, Jensen LO, Kaltoft A, Kelbaek H, Abildgaard U, Villadsen AB, Krusell LR,
Ravkilde J, Hansen KN, Christiansen EH, Aaroe J, Jensen JS, Kristensen SD, Botker HE, Madsen M, Thayssen
P, Sorensen HT, Thuesen L, Lassen JF. 3-Year clinical outcomes in the randomized SORT OUT III superiority
trial comparing zotarolimus- and sirolimus-eluting coronary stents. JACC Cardiovasc Interv 2012;5(8):812-8.
159.
Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA,
Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ, Investigators SI. Everolimus-eluting versus paclitaxel-eluting
stents in coronary artery disease. N Engl J Med 2010;362(18):1663-74.
160.
Stone GW, Rizvi A, Sudhir K, Newman W, Applegate RJ, Cannon LA, Maddux JT, Cutlip DE,
Simonton CA, Sood P, Kereiakes DJ, Investigators SI. Randomized comparison of everolimus- and paclitaxeleluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting
Coronary Stent System) IV trial. J Am Coll Cardiol 2011;58(1):19-25.
161.
Park DW, Kim YH, Yun SC, Kang SJ, Lee SW, Lee CW, Park SW, Seong IW, Lee JH, Tahk SJ, Jeong
MH, Jang Y, Cheong SS, Yang JY, Lim DS, Seung KB, Chae JK, Hur SH, Lee SG, Yoon J, Lee NH, Choi YJ,
Kim HS, Kim KS, Kim HS, Hong TJ, Park HS, Park SJ. Comparison of zotarolimus-eluting stents with
sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy
and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions)
randomized trial. J Am Coll Cardiol 2010;56(15):1187-95.
162.
Jang SJ, Park DW, Kim WJ, Kim YH, Yun SC, Kang SJ, Lee SW, Lee CW, Park SW, Park SJ.
Differential long-term outcomes of zotarolimus-eluting stents compared with sirolimus-eluting and paclitaxeleluting stents in diabetic and non-diabetic patients: 2-year subgroup analysis of the ZEST randomized trial.
Catheter Cardiovasc Interv 2012.
163.
Kim WJ, Lee SW, Park SW, Kim YH, Yun SC, Lee JY, Park DW, Kang SJ, Lee CW, Lee JH, Choi SW,
Seong IW, Lee BK, Lee NH, Cho YH, Shin WY, Lee SJ, Lee SW, Hyon MS, Bang DW, Park WJ, Kim HS,
Chae JK, Lee K, Park HK, Park CB, Lee SG, Kim MK, Park KH, Choi YJ, Cheong SS, Yang TH, Jang JS, Her
SH, Park SJ, Investigators E-DS. Randomized comparison of everolimus-eluting stent versus sirolimus-eluting
stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCEDIABETES): results from the ESSENCE-DIABETES trial. Circulation 2011;124(8):886-92.
164.
Park KW, Yoon JH, Kim JS, Hahn JY, Cho YS, Chae IH, Gwon HC, Ahn T, Oh BH, Park JE, Shim
WH, Shin EK, Jang YS, Kim HS. Efficacy of Xience/promus versus Cypher in rEducing Late Loss after
stENTing (EXCELLENT) trial: study design and rationale of a Korean multicenter prospective randomized trial.
Am Heart J 2009;157(5):811-817 e1.
165.
Park KW, Chae IH, Lim DS, Han KR, Yang HM, Lee HY, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong
MH, Hong TJ, Chung WY, Jo SH, Choi YJ, Hur SH, Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon
HK, Gwon HC, Jang YS, Kim HS. Everolimus-eluting versus sirolimus-eluting stents in patients undergoing
percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce
Late Loss After Stenting) randomized trial. J Am Coll Cardiol 2011;58(18):1844-54.
166.
Fukumoto A, Otsuji S, Takiuchi S, Ikushima M, Asano K, Terasoma K, Hasegawa K, Yabuki M,
Higashino Y. Comparison of real-world clinical outcomes between Cypher- and Taxus-eluting stents: the
GARA–GARA study. Cardiovascular Intervention and Therapeutics 2011;26(3):202-208.
167.
Kang WC, Ahn T, Lee K, Han SH, Shin EK, Jeong MH, Yoon JH, Park JS, Bae JH, Hur SH, Rha SW,
Oh SK, Kim DI, Jang Y, Choi JW, Kim BO. Comparison of zotarolimus-eluting stents versus sirolimus-eluting
stents versus paclitaxel-eluting stents for primary percutaneous coronary intervention in patients with STelevation myocardial infarction: results from the Korean Multicentre Endeavor (KOMER) acute myocardial
infarction (AMI) trial. EuroIntervention 2011;7(8):936-43.
168.
Park DW, Kim YH, Song HG, Ahn JM, Kim WJ, Lee JY, Kang SJ, Lee SW, Lee CW, Park SW, Yun
SC, Seung KB, Yang TH, Lee SG, Lee JH, Seong IW, Cheong SS, Lee BK, Lee NH, Lee SW, Lee SW, Lee K,
Kim HS, Jeon DS, Kim MK, Nah DY, Tahk SJ, Park SJ. Comparison of everolimus- and sirolimus-eluting stents
in patients with long coronary artery lesions: a randomized LONG-DES-III (Percutaneous Treatment of LONG
Native Coronary Lesions With Drug-Eluting Stent-III) Trial. JACC Cardiovasc Interv 2011;4(10):1096-103.
169.
Briguori C, Airoldi F, Visconti G, Focaccio A, Caiazzo G, Golia B, Biondi-Zoccai G, Ricciardelli B,
Condorelli G. Novel approaches for preventing or limiting events in diabetic patients (Naples-diabetes) trial: a
randomized comparison of 3 drug-eluting stents in diabetic patients. Circ Cardiovasc Interv 2011;4(2):121-9.
170.
Stone GW, Teirstein PS, Meredith IT, Farah B, Dubois CL, Feldman RL, Dens J, Hagiwara N, Allocco
DJ, Dawkins KD, Investigators PT. A prospective, randomized evaluation of a novel everolimus-eluting
coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting
Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions)
trial. J Am Coll Cardiol 2011;57(16):1700-8.
171.
Kang KW, Ko YG, Shin DH, Kim JS, Kim BK, Choi D, Hong MK, Kang WC, Ahn T, Jeon DW, Yang
JY, Jang Y. Impact of positive peri-stent vascular remodeling after sirolimus-eluting and paclitaxel-eluting stent
implantation on 5-year clinical outcomes: intravascular ultrasound analysis from the Poststent Optimal Stent
Expansion Trial multicenter randomized trial. Circ J 2012;76(5):1102-8.
172.
Suttorp MJ, Laarman GJ. A randomized comparison of sirolimus-eluting stent implantation with
zotarolimus-eluting stent implantation for the treatment of total coronary occlusions: Rationale and design of the
PRImary Stenting of Occluded Native coronary arteries III (PRISON III) study. American Heart Journal
2007;154(3):432-435.
173.
Branden BJVd, Koolen JJ, Henriques JP, Tijssen JG, Schaaf RJvd, Vermeersch PH, Suttorp MJ. A
Randomized Comparison of Sirolimus-eluting Stent Implantation with Zotarolimus-eluting Stent Implantation
for the Treatment of Total Coronary Occlusions: Primary Stenting of Totally Occluded Native Coronary Arteries
III (PRISON III trial). http://www.crtonline.org/flash.aspx?PAGE_ID=8659.
174.
Tanzilli G, Pelliccia F, Pasceri V, Speciale G, Greco C, Arrivi A, Viceconte N, Mangieri E, Gaudio C.
Randomized study on provisional stenting with sirolimus-eluting stent vs. bare metal stent for the treatment of
true coronary bifurcations: The PROSUMER (PROvisional with sirolimus-eluting vs. bare metal stents in truE
bifuRcations) study. International Journal of Cardiology 2011;146(2):240-241.
175.
Burzotta F, Trani C, Todaro D, Mariani L, Talarico GP, Tommasino A, Giammarinaro M, Niccoli G,
Porto I, Leone AM, Mongiardo R, Mazzari MA, Schiavoni G, Crea F. Prospective randomized comparison of
sirolimus- or everolimus-eluting stent to treat bifurcated lesions by provisional approach. JACC Cardiovasc
Interv 2011;4(3):327-35.
176.
Park HJ, Kim HY, Lee JM, Choi YS, Park CS, Kim DB, Her SH, Koh YS, Park MW, Kwon BJ, Kim
PJ, Chang K, Chung WS, Seung KB. Randomized comparison of the efficacy and safety of zotarolimus-eluting
stents vs. sirolimus-eluting stents for percutaneous coronary intervention in chronic total occlusion--CAtholic
Total Occlusion Study (CATOS) trial. Circ J 2012;76(4):868-75.
177.
Raber L, Kelbaek H, Ostoijc M, Baumbach A, Tuller D, von Birgelen C, Roffi M, Pedrazzini G,
Kornowski R, Weber K, Heg D, Matter C, Luscher T, Taniwaki M, Meier B, Juni P, Windecker S. Comparison
of biolimus eluted from an erodible stent coating with bare metal stents in acute ST-elevation myocardial
infarction (COMFORTABLE AMI trial): rationale and design. EuroIntervention 2012;7(12):1435-43.
178.
Raber L, Kelbaek H, Ostojic M, Baumbach A, Heg D, Tuller D, von Birgelen C, Roffi M, Moschovitis
A, Khattab AA, Wenaweser P, Bonvini R, Pedrazzini G, Kornowski R, Weber K, Trelle S, Luscher TF, Taniwaki
M, Matter CM, Meier B, Juni P, Windecker S, Investigators CAT. Effect of biolimus-eluting stents with
biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial
infarction: the COMFORTABLE AMI randomized trial. JAMA 2012;308(8):777-87.
179.
Kim JS, Kim BK, Jang IK, Shin DH, Ko YG, Choi D, Hong MK, Cho YK, Nam CW, Hur SH, Choi
JH, Song YB, Hahn JY, Choi SH, Gwon HC, Jang Y. ComparisOn of neointimal coVerage betwEen
zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT).
Am Heart J 2012;163(4):601-7.
180.
Wijnbergen I, Helmes H, Tijssen J, Brueren G, Peels K, van Dantzig JM, Van' t Veer M, Koolen JJ,
Pijls NH, Michels R. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary
intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the
Eindhoven reperfusion study. JACC Cardiovasc Interv 2012;5(3):313-22.
181.
Sabate M, Cequier A, Iniguez A, Serra A, Hernandez-Antolin R, Mainar V, Valgimigli M, Tespili M,
den Heijer P, Bethencourt A, Vazquez N, Brugaletta S, Backx B, Serruys P. Rationale and design of the
EXAMINATION trial: a randomised comparison between everolimus-eluting stents and cobalt-chromium baremetal stents in ST-elevation myocardial infarction. EuroIntervention 2011;7(8):977-84.
182.
Sabate M, Cequier A, Iniguez A, Serra A, Hernandez-Antolin R, Mainar V, Valgimigli M, Tespili M,
den Heijer P, Bethencourt A, Vazquez N, Gomez-Hospital JA, Baz JA, Martin-Yuste V, van Geuns RJ, Alfonso F,
Bordes P, Tebaldi M, Masotti M, Silvestro A, Backx B, Brugaletta S, van Es GA, Serruys PW. Everolimuseluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year
results of a randomised controlled trial. Lancet 2012;380(9852):1482-90.
183.
Mehilli J. Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main
Coronary Artery Lesions : ISAR-LEFT MAIN 2 Randomized Trial.
http://www.crtonline.org/flash.aspx?PAGE_ID=10316.
184.
Ahn JM, Park DW, Kim YH, Song H, Cho YR, Kim WJ, Lee JY, Kang SJ, Lee SW, Lee CW, Park SW,
Yun SC, Han S, Lee SY, Lee BK, Cho JH, Yang TH, Lee NH, Yang JY, Park JS, Shin WY, Kim MH, Bae JH,
Kim MK, Yoon J, Park SJ. Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in
patients with de novo long coronary artery lesions: a randomized LONG-DES IV trial. Circ Cardiovasc Interv
2012;5(5):633-40.
185.
Kadota K, Muramatsu T, Iwabuchi M, Saito S, Hayashi Y, Ikari Y, Nanto S, Fujii K, Inoue N, Namiki
A, Kimura T, Mitsudo K. Randomized comparison of the Nobori Biolimus A9-eluting stent with the sirolimuseluting stent in patients with stenosis in native coronary arteries. Catheter Cardiovasc Interv 2012;80(5):789-96.
186.
Pan M, Medina A, Suarez de Lezo J, Romero M, Segura J, Martin P, Suarez de Lezo J, Hernandez E,
Mazuelos F, Ojeda S. Randomized study comparing everolimus- and sirolimus-eluting stents in patients with
bifurcation lesions treated by provisional side-branch stenting. Catheter Cardiovasc Interv 2012;80(7):1165-70.
187.
Camenzind E, Wijns W, Mauri L, Boersma E, Parikh K, Kurowski V, Gao R, Bode C, Greenwood JP,
Gershlick A, O'Neill W, Serruys PW, Jorissen B, Steg PG, Committee PS, Investigators. Rationale and design of
the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled
trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting
stent implantation. Am Heart J 2009;158(6):902-909 e5.
188.
Camenzind E, Wijns W, Mauri L, Kurowski V, Parikh K, Gao R, Bode C, Greenwood JP, Boersma E,
Vranckx P, McFadden E, Serruys PW, O'Neil WW, Jorissen B, Van Leeuwen F, Steg PG, Committee PS,
Investigators. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting
coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet
2012;380(9851):1396-405.
189.
Kimura T, Morimoto T, Natsuaki M, Shiomi H, Igarashi K, Kadota K, Tanabe K, Morino Y, Akasaka T,
Takatsu Y, Nishikawa H, Yamamoto Y, Nakagawa Y, Hayashi Y, Iwabuchi M, Umeda H, Kawai K, Okada H,
Kimura K, Simonton CA, Kozuma K, Investigators R. Comparison of everolimus-eluting and sirolimus-eluting
coronary stents: 1-year outcomes from the Randomized Evaluation of Sirolimus-eluting Versus Everolimuseluting stent Trial (RESET). Circulation 2012;126(10):1225-36.
190.
Sakakibara T, Ishii H, Toriyama T, Aoyama T, Takahashi H, Kamoi D, Kawamura Y, Kawashima K,
Yoneda K, Amano T, Tanaka M, Yoshikawa D, Hayashi M, Matsubara T, Murohara T. Sirolimus-eluting stent vs.
everolimus-eluting stent for coronary intervention in patients on chronic hemodialysis. Circ J 2012;76(2):351-5.
191.
Chung WY, Kang J, Cho YS, Park HJ, Yang HM, Seo JB, Suh JW, Kim KI, Youn TJ, Kim SH, Chae
IH, Zo JH, Kim MA, Choi DJ. A randomized, prospective, two-center comparison of sirolimus-eluting stent and
zotarolimus-eluting stent in acute ST-elevation myocardial infarction: the SEZE trial. Chin Med J (Engl)
2012;125(19):3373-81.
192.
Song H-G, Park D-W, Kim Y-H, Ahn J-M, Kim W-J, Lee J-Y, Kang S-J, Lee S-W, Lee CW, Park S-W,
Han S, Seong I-W, Lee N-H, Lee B-K, Lee K, Lee S-W, Nah D-Y, Park S-J. Randomized Trial of Optimal
Treatment Strategies for In-Stent Restenosis After Drug-Eluting Stent Implantation. Journal of the American
College of Cardiology 2012;59(12):1093-1100.
193.
Jensen LO, Thayssen P, Tilsted HH, Ravkilde J, Junker A, Hansen HS, Hansen KN, Pedersen KE,
Sorensen HT, Thuesen L, Lassen JF, Scandinavian Organization for Randomized Trials with Clinical Outcome
SOUTIVi. Rationale and design of a randomized clinical comparison of everolimus-eluting (Xience v/Promus)
and sirolimus-eluting (cypher select+) coronary stents in unselected patients with coronary heart disease.
Cardiology 2010;116(2):73-8.
194.
Jensen LO, Thayssen P, Hansen HS, Christiansen EH, Tilsted HH, Krusell LR, Villadsen AB, Junker A,
Hansen KN, Kaltoft A, Maeng M, Pedersen KE, Kristensen SD, Botker HE, Ravkilde J, Sanchez R, Aaroe J,
Madsen M, Sorensen HT, Thuesen L, Lassen JF, Scandinavian Organization for Randomized Trials With
Clinical Outcome IVI. Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients
treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with
Clinical Outcome IV (SORT OUT IV). Circulation 2012;125(10):1246-55.
195.
Jensen LO, Thayssen P, Christiansen EH, Tilsted HH, Maeng M, Hansen KN, Kaltoft A, Hansen HS,
Botker HE, Krusell LR, Ravkilde J, Madsen M, Thuesen L, Lassen JF, Investigators SOI. 2-year patient-related
versus stent-related outcomes: the SORT OUT IV (Scandinavian Organization for Randomized Trials With
Clinical Outcome IV) Trial. J Am Coll Cardiol 2012;60(13):1140-7.
196.
Grube E, Chevalier B, Guagliumi G, Smits PC, Stuteville M, Dorange C, Papeleu P, Kaul U, Dzavik V.
The SPIRIT V diabetic study: a randomized clinical evaluation of the XIENCE V everolimus-eluting stent vs the
TAXUS Liberte paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesions. Am Heart J
2012;163(5):867-875 e1.
197.
Basalus MWZ, Tandjung K, van Houwelingen KG, Stoel MG, de Man FHAF, Louwerenburg JW, Said
SAM, Linssen GCM, Kleijne MAWJ, Van der Palen J, Huisman J, Verhorst PMJ, von Birgelen C. Twente study:
The real-world endeavor resolute versus xience V drug-eluting stent study in twente: Study design, rationale and
objectives. Netherlands Heart Journal 2010;18(7-8):360-364.
198.
von Birgelen C, Basalus MW, Tandjung K, van Houwelingen KG, Stoel MG, Louwerenburg JH,
Linssen GC, Said SA, Kleijne MA, Sen H, Lowik MM, van der Palen J, Verhorst PM, de Man FH. A
randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting
Xience V stents in real-world patients: the TWENTE trial. J Am Coll Cardiol 2012;59(15):1350-61.
199.
von Birgelen C, Tandjung K, Sen H, Basalus M, Louwerenburg JH, Stoel M, van Houwelingen KG,
Linssen G, Saïd S, Nienhuis M, Löwik M, van der Palen J, Verhorst P, de Man F. TCT-47 Two-Year Clinical
Outcome of the TWENTE Trial, a Randomized Controlled Trial Comparing Second-Generation ZotarolimusEluting Resolute Stents Versus Everolimus-Eluting Xience V Stents in Real-World Patients. Journal of the
American College of Cardiology 2012;60(17, Supplement):B15.
200.
Hofma SH, Brouwer J, Velders MA, van't Hof AW, Smits PC, Quere M, de Vries CJ, van Boven AJ.
Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial
infarction. 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute
Myocardial Infarction) trial. J Am Coll Cardiol 2012;60(5):381-7.
201.
Belder Ad. A prospective randomized trial of everolimus-eluting stents vs bare metal stents in
octogenarians: XIence or Vision for the Management of Angina in the elderly – The XIMA trial.
http://www.crtonline.org/flash.aspx?PAGE_ID=10334.
202.
Moreno R, Garcia E, Teles RC, Almeida MS, Carvalho HC, Sabate M, Martin-Reyes R, Rumoroso JR,
Galeote G, Goicolea FJ, Moreu J, Mainar V, Mauri J, Ferreira R, Valdes M, Perez de Prado A, Martin-Yuste V,
Jimenez-Valero S, Sanchez-Recalde A, Calvo L, Lopez de Sa E, Macaya C, Lopez-Sendon JL. A randomised
comparison between everolimus-eluting stent and sirolimus-eluting stent in chronic coronary total occlusions.
Rationale and design of the CIBELES (non-acute Coronary occlusion treated by EveroLimus-Eluting Stent) trial.
EuroIntervention 2010;6(1):112-6.
203.
Moreno R, Garcia E, Teles R, Rumoroso JR, Carvalho HC, Goicolea FJ, Moreu J, Mauri J, Sabate M,
Mainar V, Patricio L, Valdes M, Fernandez Vazquez F, Sanchez-Recalde A, Galeote G, Jimenez-Valero S,
Almeida M, de Sa EL, Calvo L, Plaza I, Lopez-Sendon JL, Martin JL, Investigators C. Randomized Comparison
of Sirolimus-Eluting and Everolimus-Eluting Coronary Stents in the Treatment of Total Coronary Occlusions:
Results From the Chronic Coronary Occlusion Treated by Everolimus-eluting Stent Randomized Trial. Circ
Cardiovasc Interv 2013;6(1):21-8.
204.
Smits PC, Hofma S, Togni M, Vazquez N, Valdes M, Voudris V, Slagboom T, Goy JJ, Vuillomenet A,
Serra A, Nouche RT, den Heijer P, van der Ent M. Abluminal biodegradable polymer biolimus-eluting stent
versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial.
Lancet 2013;381(9867):651-60.
205.
Kim S, Kim JS, Shin DH, Kim BK, Ko YG, Choi D, Cho YK, Nam CW, Hur SH, Jang Y, Hong MK.
Comparison of early strut coverage between zotarolimus- and everolimus-eluting stents using optical coherence
tomography. Am J Cardiol 2013;111(1):1-5.
206.
Park KW, Park BE, Kang SH, Park JJ, Lee SP, Cha KS, Rhew JY, Jeon HK, Shin ES, Oh JH, Jeong
MH, Kim S, Hwang KK, Yoon JH, Lee SY, Park TH, Moon KW, Kwon HM, Chae IH, Kim HS. The
'Harmonizing Optimal Strategy for Treatment of coronary artery stenosis - sAfety & effectiveneSS of drugelUting stents & antiplatelet REgimen' (HOST-ASSURE) trial: Study protocol for a randomized controlled trial.
Trials 2012;13.
207.
Kim H-S, Park K-W, Kang S-H, Cha K-S, Park B-E, Rhew J-Y, Chae H-KJ-H. Randomized
Comparison of PtCr-EES vs CoCr-ZES in All-Comers Receiving PCI: The HOST-ASSURE Randomized Trial.
In; 2013, Presented in San Francisco ACC '13.
208.
Natsuaki M, Kozuma K, Morimoto T, Kadota K, Muramatsu T, Nakagawa Y, Akasaka T, Igarashi K,
Tanabe K, Morino Y, Ishikawa T, Nishikawa H, Awata M, Abe M, Okada H, Takatsu Y, Ogata N, Kimura K,
Urasawa K, Tarutani Y, Shiode N, Kimura T. Biodegradable Polymer Biolimus-eluting Stent versus Durable
Polymer Everolimus-eluting Stent: a randomized, controlled, non-inferiority trial. J Am Coll Cardiol 2013.
209.
Christiansen EH, Jensen LO, Thayssen P, Tilsted H-H, Krusell LR, Hansen KN, Kaltoft A, Maeng M,
Kristensen SD, Bøtker HE, Terkelsen CJ, Villadsen AB, Ravkilde J, Aarøe J, Madsen M, Thuesen L, Lassen JF.
Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in
unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority
trial. The Lancet;381(9867):661-669.